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Chapter 1
 
Introduction
This chapter is partly adapted from: Neuromuscular imaging, Chapter 23: 
Facioscapulohumeral muscular dystrophy H.E. Kan, B.H. Janssen and N.B.M Voet, 
Edited by D. Fischer and M.P. Wattjes, Springer. 2013
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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic neuromuscular 
disorder. FSHD patients suffer from a progressive loss of muscle force due to 
replacement of muscle tissue with fat and muscle atrophy. The rate and order of 
muscle dysfunction is very variable between patients, and until today no curative 
treatment is available to these patients. Magnetic resonance imaging (MRI) is a 
tool to study muscular structure in vivo without causing any harm or risk to the 
patient. This chapter introduces the classification, genetics, histopathology and 
clinical presentation specific to FSHD. The second part of this chapter is devoted 
to the basic principles of MRI. Finally MRI findings in FSHD are discussed and an 
outline of this thesis is provided. 
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Fascioscapulohumeral muscular dystrophy
Introduction and classification
FSHD is an autosomal dominant muscular dystrophy with a previously estimated 
incidence of approximately 1 in 20.000 worldwide1,2 and recently 12 in 100.0003. 
This makes it the one of the most common hereditary muscular dystrophies, 
after Duchenne muscular dystrophy and myotonic dystrophy. The disease was 
first described by Landouzy and Dejerine in 1885 and was originally known as 
Landouzy-Dejerine disease.  
The age of onset of FSHD is usually in the second decade of life, even though age 
of onset and rate of progression vary greatly between patients4,5. The disease is 
characterized by asymmetric loss of force and atrophy of muscular tissue starting in 
the face and shoulder region. Clinically the muscle weakness is slowly progressive, 
and over time also the pelvis muscles and muscles of the legs can become 
affected6. In most FSHD patients, FSHD type 1, the disease results from a deletion 
of a repetitive element on the distal end of chromosome 4 known as D4Z47. 
Clinical presentation  
FSHD derives its name from the muscle groups that are mainly affected first: 
facial and shoulder girdle muscles. In more than 90% of cases, on first clinical 
examination the orbicularis oculi and -oris muscle are affected which leads to 
incomplete eye closure, asymmetric lips, inability to whistle and, sometimes, 
swallowing problems4,8,9. Shoulder girdle muscles, especially the scapular and 
pectoral muscles, are involved early10. An initially fairly normal deltoid muscle 
contributes to winging of the scapula on elevation of the arms (Figure 1). Tasks 
such as combing hair, brushing teeth, and reaching up become difficult if not 
impossible. 
Figure 1: Winging of the scapulae, 
back view: forward sloping of the 
shoulders, horizontal position of 
the clavicles due to the weight 
of the upper extremity and 
weakness of the trapezius muscle, 
prominence of sternoclavicular 
joints. Preferential weakness of the 
lower trapezius muscle results in 
characteristic upward movement 
of the scapula when attempting to 
flex or abduct the arms. 
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During disease progression, humeral, abdominal, pelvic girdle and lower extremity 
muscles can become involved as well. Lower abdominal muscles are weaker 
than the upper abdominal muscles, causing a “Beevor’s sign”, a physical finding 
specific to FSHD11. In the arm, only the upper arm muscles, i.e., biceps and 
triceps, are selectively involved, resulting in atrophy of the upper arm and sparing 
of the forearm muscles, which results in the appearance of “Popeye arms”. The 
onset of lower-extremity weakness is often but not always distal, typically in the 
anterior leg compartment, presenting with foot drop12,13. Asymmetric muscle 
weakness is characteristic for FSHD (Figure 2), but the underlying reason is 
unknown. Despite this asymmetric weakness, the incidence of contractures or 
scoliosis is low. About 10% of patients with FSHD have ankle contractures, and 
30% develop scoliosis4,14.
Figure 2: T1 weighted MRI image of both legs of an FSHD patient showing the asymmetry in muscle 
involvement between the legs. 
Unlike many other muscular dystrophies, cardiac complications in FSHD are rare.  
Occasionally cardiac conduction defects have been observed, although most 
authors claim no cardiac involvement15. Symptomatic respiratory weakness occurs 
in about 1% of affected individuals16. Risk factors include severe involvement with 
wheelchair confinement, moderate to severe kyphoscoliosis, and the presence of 
pectus excavatum.
Even though pain and fatigue are not symptoms commonly mentioned in 
textbooks, they often reported by patients4. A survey conducted in 107 patients 
with FSHD in the Netherlands revealed that 74% of patients experienced pain 
for more than four days per month and 58% for four or more days per week17. 
In another survey 61% of 139 FSHD patients reported severe fatigue, which is 
associated with a decreased quality of life18.
FSHD prevalence is equal over the world and has no particular racial, geographic 
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or ethnic distribution19. The median age of onset of FSHD is about 17 years and 
is usually determined in retrospect, but can vary from infancy to the seventh 
decade1. Men and women are affected equally, however, women are more 
often asymptomatic or clinical less affected20. The degree of involvement among 
patients is extremely variable, even within families, ranging from patients with very 
mild muscle weakness, who are unaware of being affected, to severe generalized 
weakness. Eventually, approximately 20% of patients require the use of a 
wheelchair14,20. The course of FSHD is considered to be slowly progressive and life 
expectancy is normal. Many patients report a relapsing course with long periods 
of quiescence interrupted by periods of rapid deterioration involving a particular 
muscle group, often heralded by pain in the affected limb13. 
Genetics and pathophysiology
In the majority of patients FSHD is caused by contraction of a large repeat 
structure called D4Z4 on chromosome 4 (FSHD1). Normally this repeat length 
varies between 11-100 units, in contrast patients with FSHD1 have one 
chromosome with 1-10 units. D4Z4 repeat contraction is associated with a 
local chromatin relaxation and the transcriptional derepression of the DUX4 
gene encoded in each D4Z4 unit7. The DUX4 gene encodes for a double 
homeobox transcription factor that, when ectopically expressed, is toxic to 
many cell types, including skeletal muscle21. Only contractions on very specific 
genetic backgrounds are associated with FSHD. Contractions of the repeat 
on other backgrounds of chromosome 4 and on chromosome 10q, where a 
highly homologous repeat structure exists, seem to be non-pathogenic22,23. 
The genetic basis for this difference in pathogenicity is the presence of a DUX4 
polyadenylation site in pathogenic backgrounds that allows for the stabilization 
of the DUX4 transcript7,24,25. Non-pathogenic backgrounds have polymorphisms 
in this polyadenylation site and therefore fail to generate stable DUX4 transcripts 
upon repeat contraction. A small subset of patients, so called FSHD2 patients, 
show the same chromatin relaxation and transcriptional derepression of DUX4 
in the absence of repeat contraction. These patients also have at least one 
chromosome 4 with a disease permissive genetic background26-28.
The pathogenesis of FSHD is largely unclear. Instead of a single structural 
mutation causing the disease a downstream pathological process is likely29. 
Because DUX4 appears to be expressed in germline cells and is repressed in 
somatic cells, it seems that muscle development pathways play a major role21.
The pathophysiology in FSHD also remains to be elucidated, and the affected 
1  
In
t
r
o
d
u
c
t
io
n
18
muscles display general dystrophic features, such as atrophy, fatty infiltration, and 
transient edema5,9. Interestingly, the disease appears to progress in a truly muscle 
specific matter, where muscles that are unaffected do not appear to show any 
abnormality. Muscle cell cultures derived from unaffected vastus lateralis muscles 
of FSHD patients are morphologically and behaviorally indistinguishable from 
cell cultures derived from healthy muscle30. Also, on a metabolic level, apparently 
unaffected muscles seem to be similar to healthy muscle, as shown by in vivo 
phosphorus-31 magnetic resonance spectroscopy (31P-MRS)31.
Histopathology
Histochemical analysis of muscle biopsies in FSHD patients show similar changes 
to other muscular dystrophies, and hence a specific marker for FSHD is absent. 
Findings include increased variation in fiber size and fiber type, fiber necrosis 
and fibrosis and an increased number of internal nuclei. Additionally, fatty 
infiltration and mononuclear inflammatory cell infiltrates have been observed32. 
The presence of small angular fibers could be an indication for regeneration. As 
disease progression differs between muscles and significant differences are also 
present in muscles, findings can vary depending on the site of the biopsy and 
disease progression9, calling for a targeted biopsy approach as will be presented 
in chapter 6.
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BOX 1: 
Muscle anatomy of the up per and 
lower leg
The leg can be divided in A) the upper leg (thigh) and B) lower leg (calf). 
The above images are transversal MRI images of the thigh and calf  10 
cm above and below the patella (kneecap) respectivly. On the MRI 
images muscle appears hypointense and (subcutaneous) fat appears 
bright. Rigid structures have low signal intensity and therefore bone and 
fibrosis appear black on conventional MRI images. 
The different muscles in the thigh (A) and calf (B) are indicated by the 
following abbreviations: rectus femoris (RF), vastus lateralis (VL), vastus 
intermedius (VI), vastus medialis (VM), sartorius (S), adductor longus 
(AL), adductor magnus (AM), gracillis (G), semimembranosus (SM), 
semitendinosus (ST), biceps femoris long head (BFL) and biceps femoris 
short head (BFS), tibialis anterior (TA), extensor digitorum, longus (EDL), 
peroneus brevis (PB), tibialis posterior (TP), soleus medialis (SOM), 
soleus lateralis (SL), gastrocnemius medialis (GM) and gastrocnemius 
lateralis (GL). 
In the thigh muscle groups are the quadriceps (RF, VL, VM, VI), medial 
muscles (G, S, AL, AM) and hamstrings (BFS, BFL, ST and SM).
1  
In
t
r
o
d
u
c
t
io
n
20
Therapy
Currently, no curative therapy exists for FSHD. Unfortunately, the clinical trials that 
have been performed in FSHD have not had great success33,34. Positive effects 
in general did not persist or failed to significantly improve the quality of life 
for the patients. However, several therapeutic strategies exist that can provide 
symptomatic and functional improvement and, with that, improve the quality of 
life of patients. Very recently Voet et al., published a paper proving that aerobic 
exercise therapy (AET) and cognitive behavioral therapy (CBT) can successfully 
reduce severe experienced fatigue35. Additionally, known complications of the 
disease can sometimes be prevented with these approaches. 
The role of exercise in many muscular remains largely untested, mostly due to 
the fear of worsening muscle weakness in dystrophies where the sarcolemmal 
membrane is structurally compromised. However this is not the case in FSHD, 
there may be a short-term effect of aerobic exercise in FSHD as it can improve 
exercise performance36. Also strength training has been proven at least to be safe 
for FSHD patients on the short-term and may be moderately beneficial34.
A number of pharmacological strategies have been tested in FSHD aiming to slow 
down or halt disease progression. Although inflammation is a common finding in 
FSHD muscle, corticosteroids failed to show improvement in strength or muscle 
mass33. Studies with albuterol showed a consistent anabolic effect in FSHD but 
the magnitude of the increased muscle mass did not translate into significant 
functional improvement in strength34. Myostatin is a protein that inhibits muscle 
differentiation and growth, however, myostatin inhibitors did not show any effect 
either6. There is evidence that phosphocreatine stores are depleted in some 
dystrophic muscle and that creatine may have cellular protective characteristics 
37,38. However in a recent Cochrane review, the authors concluded that one 
small trial of creatine was inadequate to confirm or refute a significant effect of 
creatine supplementation in FSHD39,40. Considering the complexity of the disease 
mechanism of FSHD, more insight in the pathogenic mechanism will assist 
future treatment strategies. With better understanding of the genetic pathways 
targeted gene approaches are being proposed like DUX4 gene silencing by RNA 
interference41. 
Imaging findings
Several imaging techniques such as ultrasound, X-ray computed tomography 
(CT) and magnetic resonance imaging (MRI) have been used to study muscle 
involvement in FSHD. Muscle imaging in FSHD patients mainly focused on 
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the lower extremities of the patients, and has revealed a distinct pattern of 
involvement of muscles in the upper and lower legs. In the upper leg, the 
hamstring muscles usually show fatty infiltration. In the lower legs the tibialis 
anterior and gastrocnemius medialis show early signs of fatty infiltration (Figure 3). 
In table 1 the muscles of both the lower and upper leg are listed in the order of 
their involvement in FSHD, as was found by different imaging techniques.
Calf hypertophy has been observed in a number of FSHD patients using 
quantitative ultrasound42. Absolute and relative calf hypertrophy – defined as an 
increased ratio of the calf muscles over the rectus femoris and vastus intermedius 
muscles- can be present. In the latter case, there is atrophy of the quadriceps 
muscles.
Fat replacement and/or atrophic lesions of anterior muscles of the lower legs 
(mainly the tibialis anterior) and the posterior muscles from the upper legs 
(hamstrings) is common. Interestingly, muscle damage has even been observed 
in early stages of the disease, which is one of the most relevant CT findings for 
FSHD43. The asymmetry of the lesions, which generally is considered one of the 
main characteristics of this disease, is also apparent on CT, as is damage to the 
paraspinal muscles44. In general, the CT findings in FSHD are consistent, except 
for the upper arm muscle involvement.  In most patients anomalies were found in 
the brachial biceps and – triceps, and the scapular girdle43. In contrast a patient 
with no involvement in the shoulder, mid-arm and pelvic muscles has been 
reported44,45. 
Lower leg Upper leg
1. Tibialis anterior 1. Semimembranosus
2. Gastronemius medialis 2. Biceps femoris
3. Extensor digitorum longus 3. Semitendinosus
4. Soleus 4. Adductor group
5. Peroneal (brevis and longus 5. Vastus lateralis, intermedius and femoris
6. Gastrocnemius lateralis
7. Tibialis posterior
Table 1: Muscles of the lower extremities in the order of their temporal involvement found by in vivo 
imaging. Composite from references 5, 9, 46 and 47. 
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BOX 2:
Facioscapulohumeral Dystrophy - 
Key Points
• FSHD is characterized by asymmetrical loss of force as well as 
atrophy and fatty replacement of muscular tissue starting in the face and 
shoulder region. 
• In the majority of patients, FSHD is caused by contraction of a 
large repeat structure called D4Z4 on chromosome 4. However, the 
pathogenesis is still largely unclear.
• In the lower limbs, fatty replacement of muscle tissue mostly occurs in 
the tibialis anterior, gastrocnemius medialis, and hamstring muscles, as 
shown by MRI, US, and CT.
• FSHD appears to progress in a truly muscle-specific fashion, where 
muscles with no fatty replacement of muscle tissue also show no 
metabolic abnormalities.
• Fatty replacement observed on T1-weighted MRI scans correlates with 
most muscle strength tests, which indicates that MRI can be helpful as a 
marker of disease progression.
• Currently, there is no curative therapy for FSHD, although therapeutic 
strategies exist that can alleviate the patient’s symptoms and provide 
functional improvement.
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Magnetic Resonance Imaging
Introduction
Magnetic Resonance Imaging (MRI) is a imaging technique widely applied in the 
medical field to study body anatomy and function, in health and disease. The 
technique is an application of nuclear magnetic resonance (NMR). NMR is the 
selective absorption of high-frequency radio waves by certain atomic nuclei that 
are subjected to an appropriately strong stationary magnetic field.
In 1946 Felix Bloch and Edward Purcell were the first to perform a successful 
NMR experiment48,49. Even though they discovered NMR simultaneously they did 
so independently from each other.  In 1952 they were awarded the Nobel Prize 
in Physics for their work. The sensitivity of NMR was much improved after the  
introduction of short intense radiofrequency (RF) pulses and Fourier transformation 
50. Richard Ernst was awarded the Nobel Prize in Chemistry for these innovations, 
making MRI more feasible. With the implementation of magnetic field gradients 
MR imaging was introduced, of which its value was demonstrated as early as 
in 1973 by Paul Lauterbur51 and Peter Mansfield52. They jointly received the 
Nobel Prize in Physiology or Medicine in 2003 for these contributions. The first 
human MRI body scan was performed in 197753,54 since then the field has grown 
enormously and now-a-days there are around 25.000 MRI systems in use55.
Physical description
To understand the principles of MRI electromagnetic concepts and even quantum 
mechanics need to be discussed. Here I will give a classical description, which 
still involves many definitions. All will be explained in the text but in addition a 
summarizing table is provided. 
Imagine a charged particle with a certain mass that is rotating around a fixed 
point at a constant distance and with a constant speed. This can be considered 
as a current loop and will create a magnetic moment (Figure 4). This particle 
will continue its motion until an external force is applied. This property is called 
angular momentum, and depends on the speed and mass of the particle and the 
circumference of the loop it is making.  The magnetic moment (μ) that is created 
by the particle depends on its angular momentum and on an intrinsic property of 
the particle called the gyromagnetic ratio (γ).
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Momentum (p) The parameter describing that an object will continue its motion until 
an external force is applied (p = m·v)
Angular momentum (L) The parameter describing that an object will continue its rotational 
motion until an external force is applied (L = r x p)
Magnetic moment (µ) Magnetization created by a charged object rotating around a fixed 
point (µ = γ·L)
Gyromagnetic ratio (γ) Ratio between magnetic moment and angular momentum of a nucleus 
(radians per second per Tesla, rad s-1 T-1)
Precession Movement of rotation axis of an object due to external (magnetic) force
Spin Intrinsic angular momentum of an atomic nucleus
Main magnetic field (B0) Refers to external magnetic field inside a MR magnet bore (Tesla, T)
Larmor frequency (ω0) Characteristic frequency at which the magnetic moment will precess if 
placed in a magnetic field, depends on γ and B0  (ω0 = γ· B0)
Net magnetization Magnetic moments per volume
RF Pulse (B1) Magnetic field oscillating in the radio-frequency range during a short 
period (µs-ms range)
Coil Device to transmit and receive oscillating electromagnetic fields
Table 2: Definitions of parameters used in the physical description of MRI
Figure 4: Charged object rotating around a fixed point can be considered a current loop and will create 
a magnetic moment (μ).
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Atomic nuclei rotate around their axes and therefore have an angular momentum. 
The intrinsic angular moment of an atomic nucleus is called spin. All atomic nuclei 
have a spin. However not all atoms have a magnetic moment. Only if the atomic 
nucleus has a non-zero spin it can create a magnetic moment, this is the case for 
proton (1H), carbon (13C) and phosphorous (31P).  
Until now I have described spin systems in the absence of a magnetic. If the 
object is placed inside a magnetic field, like inside the bore of an MRI, a torque 
will be generated. This will cause the magnetic moment of the object to rotate 
(precess) around the main magnetic field (B0) with a characteristic frequency, the 
Larmor frequency (Figure 5). The Larmor frequency is a characteristic of the atomic 
nucleus as it only depends on its gyromagnetic ratio and the strength of the main 
magnetic field, see equation 1.
 ω0 = γ· B0        eq. 1
Figure 5: Left: Nuclear spin with a magnetic moment (μ) will precess with the Larmor frequency if 
placed in a (external) magnetic field (B0). Right: An ensemble of α- and β-spins (spins up and down 
respectively) will result in a net magnetization (M0) along B0.
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If the spin quantum number of the object is ½ (which is the case for 1H, 31P and 
13C), there are only two possible energy levels for the spins. These are referred to 
as “spin up” (or α) and “spin down” (or β). 
With MR experiments it is not possible to observe single spins but always a 
population of spins is considered. Imagine an ensemble of objects with spin 
½, some spins will reside in energy level α and some in energy level β. If equal 
amount of spins would reside in energy level α as in β no net magnetization would 
be left, as the magnetization of α and β spins are in opposed directions (Figure 6). 
However, because there is a small energy difference between the α and β spins a 
small difference in population between these two spin states exists. This difference 
depends on γ, the magnetic field strength and the temperature according to 
equation 2. 
           
         eq. 2
The net magnetization (M0) is a static vector aligned with the main 
magnetic field. In order to detect this magnetization, this equilibrium 
state needs to be disturbed. Only magnetization orthogonal to 
the main magnetic field can be observed with an MRI experiment, 
where it will precess with the Larmor frequency. Therefore the 
magnetization vector needs to be rotated towards the transverse 
plane. 
Figure 6: An ensemble of spins all rotating with the larmor frequency around B0. The energy difference 
between the spins in the up (α) and down (β) state results in a net magnetization along B0.
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The magnetization (M) is rotated towards the transverse plain by applying a 
second magnetic field  (B1), orthogonal to the main magnetic field (Figure 7). 
This magnetic field is oscillating in the radiofrequency (RF) range, and is therefore 
referred to as RF-pulse. In practice the RF-pulse is generated by a current running 
through a loop (a transmit coil). Because two external magnetic fields (B0 and B1) 
act on the magnetization simultaneously, its trajectory during this period is rather 
complex. This is simplified if we switch to a rotating frame of reference. In this case 
the x- and y-axis (the transverse plane) rotate with the Larmor frequency and the 
magnetization is simply tilted towards the transverse plain. The rotation angle, 
of the magnetization depends on the duration and the power of the RF-pulse 
(θ=2π γ B1 t). When all magnetization ends up in the transverse plane the rotation 
angle was 90o and the corresponding RF-pulse is called a 90o-pulse. When the 
power or duration of the pulse is doubled the rotation angle is 180o and all the 
magnetization is aligned along the –z direction.
Figure 7: Excitation of magnetization in the rotating frame of reference. (A) The net magnetization (M0) 
is aligned to the main magnetic field. The phases of the individual spins are randomly distributed (no 
phase coherence), so there is no net magnetization in the transverse plane.  (B) A second magnetic 
field (B1) is applied rotating the magnetization towards the transverse (xy-plane). This creates phase 
coherence of individual spins. When the second magnetic field is switched off and all magnetization 
has ended up along the y’-axis, this is called a 90o pulse.
When the RF-pulse is turned off, after a 90 o-pulse, the spins continue to rotate in 
the transverse plane. Due to small variations in the local magnetic field, all spins 
will rotate with slightly different frequencies. Therefore phase coherence is lost 
rapidly. This process is called T2-relaxation or spin-spin relaxation (Figure 8). The 
signal loss depends on the time after the 90o-pulse and follow a mono-exponential 
decay from which the T2 time-constant can be derived. With a spin-echo 
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Figure 8: T2-relaxation. (A/1) After a 90o pulse all spins have the same phase (the spins are in phase 
coherence).  (2 and 3) Due to local variations in the magnetic field spins rotate with a slightly different 
frequency. Therefore phase coherence is lost and the signal from the net magnetization decreases 
over time. This is called T2-relaxation. The decaying signal is called the free induction decay (FID) and 
follows a mono-exponential function, from which the T2 time-constant can be derived. 
Figure 9: Spin-echo experiment, from which the T2 relaxation time can be derived. Immediately after 
the 90o-pulse there is maximal phase coherence and thus magnetization in the transverse plane. Due 
to small variations in the local magnetic field spins rotate with a slightly different frequency leading to 
phase accumulation over time. After half the echo-time (TE/2) the spins are flipped 180o after which 
they start to rephrase due to the same small variations in the local magnetic field. At the echo-time 
rephrasing is complete and a spin-echo is formed. The signal decays due to T2 relaxation and depends 
on the echo-time (TE). The T2 time-constant can be derived by performing a series of experiments 
varying TE and fitting the signal according to equation 3.    
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experiment the signal decay is a function of echo-time and T2 time of the sample 
(i.e. tissue), see figure 9. From such an experiment the T2 time-constant can be 
derived from equation 3.
           
         eq. 3
When magnetic field inhomogeneities occur on the macroscopic level the 
transverse magnetization is lost even more rapidly. The combined effect of this 
magnetic field inhomogeneities and T2-relaxation is called T2*-relaxation (1/T2* = 
1/T2 + γΔB0).
Another form of relaxation is T1-relaxation or longitudinal relaxation. After the RF-
pulse is turned off the magnetization will return to the equilibrium situation, which 
is in alignment with the main magnetic field. 
T1 and T2-relaxation are characteristic for a specific tissue, and by manipulating 
the order, timing, and magnitude of the RF-pulses contrast of an image can be 
changed towards the different relaxation properties. 
As long as there is magnetization in the transverse plane it will precess around the 
main magnetic field. A receive coil is able to pick-up this precessing magnetization 
as it will induce an oscillating current. The signal received by the coil is called the 
free induction decay (FID) (Figure 10). 
M
xy
(TE)=M
0
e−TE/T2
Figure 10: Magnetization relaxes back to the main magnetic field (left). The magnetization sweeping 
through the transverse plane generates a current that is picked-up by a receive coil (right). This signal is 
called a free induction decay (FID).
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MR experiments can be divided in imaging (MRI) and spectroscopy (MRS) 
experiments. The combination of both, called MRSI (magnetic resonance 
spectroscopic imaging), also exists. In MRSI experiments the location of the 
obtained spectra is resolved. 
Magnetic resonance imaging
In the case of MRI the water protons signal is commonly observed. Water is highly 
abundant in biological tissues and is therefore the “easiest” ensemble of spins 
to observe. As explained in the previous section the spins will rotate with the 
Larmor frequency around the main magnetic field, and if the net magnetization 
has a component in the transverse plane this can be measured with a receive 
coil. However if all spins were exposed to the same RF-pulse and subsequently 
all feel the same main magnetic field they will precess with the same frequency 
and it is impossible to resolve the location of the signal. An MRI-scanner is 
therefore employed with gradient sets that can apply magnetic field gradients in 
three orthogonal directions. These gradients cause (well characterized) location 
dependent variations in the magnetic. As a consequence the spins will precess 
with Larmor frequencies that depend on their location. 
Contrast in MRI images is caused by differences in T1 and T2 relaxation times 
of different tissue types. The contrast can by enhanced by tweaking the MRI 
sequence (scan), by adjusting the order, the timing, and the magnitude of the 
RF-pulses. As explained in the previous section there are two types of relaxation: 
T1 and T2 relaxation. T1 weighted images are obtained with sequences using a 
short repetition time (TR) and echo time (TE) (less than ~750 ms and less than~40 
ms respectively), while T2 weighted images are recorded using a long TR and 
TE (more than ~2000 ms and more than ~80 ms respectively). A general rule 
is that the more rigid the tissue the shorter the T2 relaxation time. Tissues like 
bone and fibrosis therefore appear a black on these images. The T2 relaxation 
time of muscle is shorter than that of fat, while it will shift towards the value of 
fat when edema/inflammation is present in the muscle. Therefore T2 distribution 
in pathogenic muscle can be used to quantify its tissue composition. In this way 
natural progression or treatment effectiveness can be studied9,56,57. In this thesis we 
will use quantitative T2-MRI to calculate the amount of fatty infiltration in muscles 
of the participants. This method is described in BOX 3.
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BOX 3: Quantitative determination of 
fat-fraction by T2 analysis -qT2-MRI-
When spins are excited their 
direction is flipped into the 
transversal (xy) plane, and 
start to process in that plane 
with the Lamor frequency (ω0). 
As long as spins are oriented 
in the transversal plane they 
experience T2 relaxation and 
start to dephase. In a spin-echo 
experiment the signal intensity 
drops exponentially with 
echo time as described in the 
subsequent equation.
The T2 relaxation time is 
characteristic for the tissue, fat 
has a relative long relaxation 
time (140 ms at 3T) while 
muscle has a relative short T2 
relaxation time (40 ms at 3T). 
When a signal from one voxel actually rises from two tissue types, e.g. fat (subscript f) 
and muscle (subscript m), the afore-mentioned formula becomes bi-exponentially:
Where A stands for amplitude of the signal attributed to either fat or muscle. So when 
signals are recorded at multiple echo-times a bi-exponential function can be fitted to 
the data and reveal the amplitudes of the muscle and fat signal. The fat-fraction (Ff) 
and muscle fraction (Fm) can then be determined by the following formulas:
An extensive description and justification for the assumptions in this method can be 
found in a publication of Kan et al., in Neuromuscular disorders (2009).
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Magnetic resonance spectroscopy
Contrary to MRI, MRS considers different spins (not only the water protons). As 
was explained earlier the Larmor frequency depends on the gyromagnetic ratio 
and on the main magnetic field. However the main magnetic field felt by the spin 
can be slightly different from the applied main magnetic field. This is because 
electrons from its own and neighboring nuclei can shield the main magnetic 
field. The resulting shift in resonance frequency is commonly referred to as 
chemical shift. The Larmor frequency is therefore also dependent on the chemical 
environment of the nucleus. When a range of frequencies is being recorded the 
spectrum can reveal information on metabolic compounds present in the tissue. 
MRS can be applied to all nuclei that have a spin and that are present in biological 
tissues. In this thesis 1H, 31P and 13C spectroscopy are discussed. Because of the 
lower concentration in biological tissues and lower γ 31P and 13C MRS suffer from 
lower signal to noise compared to 1H-MRS. In addition the natural abundance of 
13C is only 1.1%, unlike 1H and 31P that both have a natural abundance of (~)100%. 
1H MRS
Nearly all metabolites contain protons, 1H MRS is therefore a powerful technique 
to study important biological compounds in intact biological tissues. Intra- and 
extramyocellular lipids (IMCL and EMCL), and creatine in muscle are clearly 
distinguishable in the 1H spectrum (Figure 11). Because the signal from water is 
usually dominating the spectrum it is often suppressed with a water-suppression 
technique.  However when in addition a water-unsuppressed spectrum is recorded 
the metabolites can be absolutely quantified by using the water signal as a 
reference. The water concentration of most tissues is known and is presumed to 
be constant. 
31P MRS
The concentration of 31P spins in metabolites in the body is much lower compared 
to the 1H spin. As a consequence 31P MRS is a less sensitive technique and this 
leads to longer scanning times or larger voxels (the pixels of an MRSI experiment). 
An advantage of 31P is the simple spectrum, in which the resonances are well 
separated. In spectra of muscle inorganic phosphate (Pi), phosphocreatine (PCr) 
and adenosine triphosate (ATP) resonances can be identified (Figure 12). ATP 
is often called the “molecular unit of currency” of intracellular energy transfer 
and contains three phosphorous atoms (α, β and γ)58. If suddenly a high demand 
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Figure 11: Proton magnetic resonance spectrum of muscle in a healthy male volunteer at 3 Tesla from 
a 15 x 15 x 15 mm3 voxel positioned in the vastus lateralis muscle. In the water suppressed spectrum 
(acquired with a STEAM-sequence, TR/TE 3000 ms / 270 ms, 256 averages) distinguishable resonances 
are that of IMCL and EMCL and creatine. Water, resonating at 4.7 ppm, dominates the proton 
spectrum and is therefore suppressed to avoid that it spoils the signals of the compounds of interest.
Figure 12: Phosphorous (31P) spectrum from human muscle collected at 3 Tesla with 12 averages and 
a repetition time of 1000 ms. 31P MRS suffers from lower signal to noise compared to 1H MRS because 
of the lower concentrations present in biological tissues and smaller γ. The 31P spectrum is relatively 
simply as it only contains a few metabolites. The tissue pH can be determined from the frequency 
difference between the Pi and PCr resonances.
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of energy (ATP) occurs its level can be maintained by synthesis from PCr and 
adenosine diphoshate (ADP) by the creatine kinase (CK) reaction. This reaction 
depends on the myocellular pH, which can be calculated from the frequency 
difference between Pi and PCr in the 31P spectrum. 
13C MRS 
Because of the low natural abundance and low γ of 13C-carbons 13C MRS suffers 
from low sensitivity. Compounds that occur at relatively high concentration in 
muscle, such as creatine and glycogen, can be observed by natural abundance 
13C MRS59,60. A major advantage of 13C MRS is its large chemical shift range so that 
most resonances are easily separated. The 13C spectrum of human muscles is very 
broad and is commonly dominated by signals from lipid molecules. Because of 
the low natural abundance of 13C it has the advantage that labeling studies can 
be applied61,62. With natural abundance MRS and MRI only the static (or steady 
state) situation is investigated. By increasing the amount of 13C (the label), by for 
instance oral supplementation, dynamic conversions can be followed. Such an 
experiment is described in chapter 5 of this thesis, in which participants ingested 
13C-enriched creatine and the uptake and breakdown is followed by means of 13C 
MRS.
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MRI findings in FSHD
The first MRI study in a FSHD patient was described in 199646. This study also 
included Limb-girdle and Becker muscular dystrophy patients. A finding not 
specific to FSHD but relevant to all muscular dystrophies, was that fat infiltrated 
muscular tissue has a longer T2 relaxation time compared to healthy muscular 
tissue. Since then, several MRI studies of FSHD patients have been published. 
In general, MRI findings in FSHD patients show that the tibialis anterior muscle 
presents with the most severe fatty replacement, followed by the gastronemicus 
muscle, especially in the gastonemicus medialis. The peroneal muscles are 
mostly unaffected. In the upper legs, the hamstrings are most affected, and the 
vastus muscles are least affected5. Remarkably, the asymmetrical involvement 
- considered a main characteristic of FSHD- is only evident in 15% of the 
investigated leg muscle pairs5. 
The level of fatty replacement of muscle tissue can also be correlated with muscle 
strength. A four-point semi-quantitative visual scale is used to evaluate fatty 
infiltration based on T1-weighted images63. This scale rates the muscles according 
to the amount of visible intramuscular fat using the intensity of subcutaneous fat as 
a reference; a muscle is graded as 1 if the signal intensity corresponds to normal 
muscle intensity and scored 4 if the signal intensity is the same as that of the 
subcutaneous fat. Muscle strength is often determined on the scale of the Medical 
Research Council (MRC-scale)64,65. The level of fatty infiltration usually correlates 
well with muscle strength for hip extension, hip abduction, hip adduction, knee 
flexion, knee extension and ankle dorsal flexion. However, grading scores of the 
involved muscles of hip flexion and ankle plantar flexion do not correlate as well 
with the corresponding MRC scores5. This could be due to the action of unaffected 
synergistic muscles, which may compensate for loss of force in affected muscles 
tested during the same maneuver. In the case of ankle plantar flexion strength, 
the weakness of the medial gastrocnemius muscle is often compensated by 
other, relatively spared, flexor muscles in the calf. For hip flexion the discrepancy 
between the MRC score and the MRI grading is probably due to the variable 
affection of muscles involved in flexion of the hip. 
Energy metabolism in muscles of patients with FSHD is also affected. Spatially 
resolved 31P-MRS of muscles with high level of fat shows higher tissue pH and 
a lower PCr over ATP ratio compared to that of healthy controls. Muscles that 
appeared normal on T1 weighted images and therefore do not have extensive 
fatty replacement do not show changes compared to control subjects31, indicating 
that in FSHD disease processes are limited to muscles that have abnormal levels of 
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fatty infiltration, and that the disease progresses in a truly muscle-specific fashion 
The lower PCr over ATP ratio likely indicates a disturbed energy metabolism and 
secondary mitochondrial dysfunction, or alternatively, it may represent a change 
in fiber type composition, if the fraction of oxidative fibers, which have lower 
PCr/ATP ratio’s66,67, increase due to preferred involvement of type II fibers. Fat-
suppressed T2-weighted images [Turbo Inversion Recovery Magnitude (TIRM)] 
sometimes show hyperintense areas in some of the muscles, indicating the 
presence of edema as a sign of inflammation (Figure 13)9,56,68,69. These results 
correspond well with biopsy findings, where mononuclear inflammatory cells are 
occasionally observed32,70. 
Figure 13: TIRM and T1 weighted images of 77-year-old male FSHD patients. A) Hyperintense areas 
are present in the VM and VL, as indicated by the arrows. The hyperintensities are caused by edema, 
suggesting that an inflammatory process is active in those muscles. B) The edema is visual on the TIRM 
image but the same areas look “normal” on the T1 weighted image. 
In FSHD it is common to see the TIRM hyperintensities adjacent to the fatty infiltration within the 
muscle. This may indicate that it is a consequence of the fatty infiltration progression or that it part of 
the disease process preceding fatty replacement.
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Outline of the thesis
The general aim of this thesis was to uncover pathophysiological features of FSHD 
non-invasively by MR imaging and spectroscopy. For that purpose we studied the 
MRI results in relation to the clinical presentation of the patients, investigate the 
general pattern of fatty replacement of muscle tissue, it’s location, distribution and 
natural progression, and alterations in the high-energy phosphate metabolism. 
Additionally, we employed fat-fraction determined by MRI to a clinical trial in 
FSHD and explored how MRI can provide specialized tools to study FSHD, tools 
that could also be applied to other muscular dystrophies.  
Even though FSHD has been described clinically for a long time, quantitative 
muscle MRI study of an FSHD patient was as recent as 199646. Thereafter MR 
researchers focused on the tongue71 and brain72,73 of the patients and only in 
2006 the first muscle MRI study of a patient cohort (18 patients) was described5. 
Until the start of the work described in this thesis, in December 2009, that work 
and the development of the fat-fraction determination by qT2-MRI for FSHD 
(explained in BOX3) was the only available scientific literature on muscle MRI in 
FSHD9. Therefore we first decided to study the muscles of FSHD patients in more 
detail by MRI. In chapter 2 we performed extensive and quantitative lower limb 
MRI and MRS exams in a large group (N=41) of well-characterized FSHD patients. 
We addressed the following questions. What is the natural distribution of fatty 
infiltration? How is this related to energy metabolism? Is there prevalence for 
specific muscles to be affected and does fatty infiltration vary within muscles? 
What is the natural progression over time and what are the predictive signs of 
progression? How do the MRI and MRS results relate to the clinical presentation of 
the patients? 
The clinical state of a patient can be scored on a clinical severity scale or by their 
maximal muscle force (see chapter 2). Another frequently used clinical tool to 
image muscle condition is ultra sound (US), which has the obvious advantages 
of being cheap, fast and easy compared to MRI. In chapter 3 we investigate 
how quantitative muscle US (QMUS) relates to quantitative MRI (QMRI) in a small 
group of five FSHD patients. We compared both techniques on their ability to 
depict muscle pathology, with respect to changes in muscle architecture and 
different stages of dystrophy. We evaluated whether the modalities withhold 
complementary information or overlap, and we discuss the settings in which each 
modality would be preferred. 
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Besides the use of MRI as a diagnostic or non-invasive research tool to 
quantitatively study and describe the muscle condition of the patients it can 
also be used in the evaluation of interventions. Severe fatigue is a common 
problem in FSHD and is reported to be present in over 60% of the Dutch patient 
population18. Aerobic exercise training (AET) and cognitive behavioral therapy 
(CBT) have been proposed by our group to improve impairment in FSHD based 
on a FSHD specific model as interventions to alleviate fatigue and its effectiveness 
was tested in a randomized clinical trial74. As effects on individual muscles are 
not detected in these studies, we investigated the intervention effects on the 
fatty infiltration rates of muscles in FSHD patients. We therefore used qT2-MRI to 
quantify the fatty infiltration progression and compared this rate between a control 
group and intervention groups. The results of this study are described in chapter 
4. 
An often proposed treatment for patients with muscle disorders is creatine 
supplementation75. Creatine is an endogenous compound and is recognized as 
a effective nutritional compound for sportsmen and for improving symptoms 
in a variety of diseases76. However the individual responsiveness to creatine 
supplementation is very variable77,78.  In chapter 5 we present a method to 
determine the creatine uptake and turnover rate in a muscle specific manner. 
Therefore, we employed 13C MRSI and oral administration of 13C-4 labeled 
creatine. We tested this method in two healthy young male and two young female 
volunteers, one male over 80 years old and two FSHD patients. 
Throughout this thesis it will become clear that FSHD is a focal disease, and also in 
the creatine supplementation study we found variability in the uptake of creatine 
between muscles of single individuals. And even though imaging is gradually 
becoming more acknowledged by the clinicians and researchers as a valid tool 
in the field of muscle diseases, still many biopsies in the context of research and 
diagnostics are being performed. However because of the disease focality as we 
found in FSHD, biopsies may present false positives or give a false representation 
of the true whole muscle condition. To reduce sampling error a targeted approach 
is more appropriate. In chapter 6 we present a novel method to obtain muscle 
biopsies, called “myonavigation”. With myonavigation biopsy first a diagnostic 
MRI exam is performed, on which the targeted muscle area is determined. The 
needle trajectory is planned on a 3D MRI image and after the needle is placed a 
control 3D MRI is performed and the location is either confirmed or the needle 
is adjusted until the location can be confirmed to be on the exact target. In this 
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chapter we discuss the safety of the method and show that the focality as we have 
previously seen on MRI to be present in FSHD muscles can be confirmed with 
histology. 
A summary of the findings of this thesis and future perspectives are provided in 
chapter 7.
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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is an untreatable disease, 
characterized by asymmetric progressive weakness of skeletal muscle with 
fatty infiltration. Although the main genetic defect has been uncovered, the 
downstream mechanisms causing FSHD are not understood. The objective of this 
study was to determine natural disease state and progression in muscles of FSHD 
patients and to establish diagnostic biomarkers by quantitative T2 MRI (qT2-MRI) 
of fat infiltration and phosphorylated metabolites.
MRI was performed at 3T with dedicated coils on legs of 41 patients (28 men/13 
women, age 34-76 years), of which eleven were re-examined after four months 
of usual care. Muscular fat-fraction was determined with multi spin-echo and T1 
weighted MRI, edema by TIRM and phosphorylated metabolites by 3D 31P MR 
spectroscopic imaging. Fat-fractions were compared to clinical severity, muscle 
force, age, edema and phosphocreatine (PCr)/ATP. Longitudinal intramuscular fat-
fraction variation was analyzed by linear regression.    
Increased intramuscular fat correlated with age (p<0.05), FSHD severity score 
(p<0.0001), inversely with muscle strength (p<0.0001), and also occurred sub-
clinically. Muscles were nearly dichotomously divided in those with high and 
with low fat-fraction, with only 13% having an intermediate fat-fraction. The 
intramuscular fat-fraction along the muscle’s length, increased from proximal to 
distal. This fat gradient was the steepest for intermediate fat infiltrated muscles 
(7%±1% per cm, p<0.001). Leg muscles in this intermediate phase showed a 
decreased PCr/ATP (p<0.05) and the fastest increase in fatty infiltration over time 
(18%±15% per year, p<0.001), which correlated with initial edema (p<0.01), if 
present. Thus, in the MR assessment of fat infiltration as biomarker for diseased 
muscles, the intramuscular fat distribution needs to be taken into account. Our 
results indicate that healthy individual leg muscles become diseased by entering a 
progressive phase with distal fat infiltration and altered energy metabolite levels. 
Fat replacement then relatively rapidly spreads over the whole muscle. 
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common 
hereditary muscular disorder1. The disease is characterized by progressive 
asymmetric weakness and fatty infiltration of skeletal muscles. In recent years it 
was demonstrated that FSHD is associated with a contraction of D4Z4 repeats on 
chromosome 4q352, leading to lost repression of DUX4, a protein that exerts toxic 
effects on muscle cells3. 
Even though the most important genetic event for the disease seems to be 
identified, a causative treatment is not yet available4. Progress is hampered 
because the trigger for DUX4 expression and the further unfolding of disease 
processes leading to fatty infiltration and muscle weakness are not known. Thus 
clarification of the underlying mechanisms is expected to offer clues for a more 
targeted approach in the search for treatment5. Understanding these mechanisms 
first requires that some key questions concerning the process of fatty infiltration 
are addressed. What is the natural distribution of fatty infiltration? How is this 
related to clinical severity, to muscle weakness and to energy metabolism? Is there 
prevalence for specific muscles to be affected and does fatty infiltration vary within 
muscles? What is the natural progression over time and what are predictive signs 
of progression?
To answer these questions and to evaluate treatment effectiveness, the use of 
a non-invasive quantitative imaging method, such as MRI, is essential. Unlike 
biopsies, MRI is not limited to a single location, and longitudinal data can be 
collected without risk for the patient. MR of fatty infiltration in muscles has been 
used to study muscular disorders like Duchenne muscular dystrophy6,7. We have 
introduced a quantitative MRI measure of fatty infiltration in muscles based on T2 
relaxation time analysis and demonstrated its value in a preliminary study of FSHD 
patients8. Phosphorus MR spectroscopy has been used extensively to investigate 
the energy status of diseased muscles9-15. Recently it was also introduced in a pilot 
study with FSHD patients16.
Until now quantitative MR imaging studies were performed in limited numbers 
of patients. However, because of the variability in age of onset and in degree 
of disease severity17, a study of its pathophysiology requires the participation of 
a relatively large number of well described patients. The main aim of this study 
was to determine natural disease state and progression by quantitative MRI of 
skeletal muscles in the legs of a large, well-characterized cohort of genetically 
confirmed FSHD patients. In particular we wanted to address the aforementioned 
pathophysiological questions to ultimately uncover clues on disease mechanism 
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and to establish MRI biomarkers with prognostic and predictive value for 
personalized assessments. 
Materials and Methods
Patients and study design
We recruited 41 FSHD patients from the local neurology department (28 men/13 
women, age 21-81 years, see Table 1 for patients demographics). Of 36 patients 
the upper leg (‘thigh’) was examined, they were selected from a group of 
patients that were entering a clinical trial to assess the effects of rehabilitation 
intervention18. In addition we included the MR exams of the lower leg of five 
patients from a previous study8 , which were re-analyzed in the exact same way as 
the MR exams of the aforementioned patients (vide infra). 
Eleven patients (8 men/ 3 women, age 34-76 years) were randomly selected, 
from the group that underwent an MR examination of the thigh, for a follow-up 
measurement after a period of four months. During this period these patients were 
instructed to maintain a normal level of activity (‘usual care’). 
All patients were clinically and genetically diagnosed with FSHD and able to 
walk independently (ankle-foot orthoses and canes were accepted). Patients 
were all unrelated except for one mother and son (patients #7 and #37). Disease 
severity was assessed with the Ricci score19 and maximum voluntary isometric 
extension (quadriceps) and flexion (hamstrings) of the knee were measured with 
a quantitative fixed myometry testing system20. Ethical approval was obtained 
from the Radboud university medical center review board, and written informed 
consent was obtained from all subjects.
MR methods
MR measurements were performed on a 3T MR system (TIM Trio, Siemens, 
Erlangen, Germany). Subjects were positioned feet first supine inside the magnet 
bore. Images were acquired with a home-built proton birdcage radiofrequency coil 
(inner diameter 25 cm).
In 36 patients, the least affected thigh, according to the subject’s own experience 
was examined, unless there were contraindications (e.g. a previous fracture 
or recent injury). A fish oil capsule was positioned at one third of the distance 
between the spina iliaca anterior superior and the patella and served as a 
landmark for exact matching of the imaging slices between the baseline and 
follow-up measurements. For the MR examinations of leg, the upper end of the 
proton coil was positioned at the center of the patella. 
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Patient 
nr.
Ricci-score Sex Age 
(years)
FSHD duration 
(years)
1 0 f 21 15
2 1.5 f 25 2
3 1.5 m 31 5
4* 2 m 34 3
5* 3 m 34 9
6 1.5 m 38 17
7 2 m 38 16
8* 3 m 39 19
9 1 f 42 5
10 3.5 m 44 32
11* 2 m 48 14
12 4 m 49 40
13 3.5 m 50 14
14 1.5 f 50 1
15 1.5 f 51 6
16* 4 m 52 19
17* 3.5 m 53 9
18 4.5 f 54 24
19* 3 f 55 1
20* 1.5 m 55 21
21 2 f 56 2
22 2 f 56 22
23 3.5 m 57 17
24 4 m 57 41
25 4 m 58 41
26* 2 f 59 22
27 3 m 59 41
28 4 m 60 9
29 3 m 61 22
30 3.5 m 61 17
31 4 f 63 31
32 4 m 64 15
33 4 m 66 30
34 3 m 66 9
35* 4.5 f 66 49
36 3 m 66 6
37 3 f 68 12
38 2 m 69 na
39 3 m 69 19
40* 3.5 m 76 4
41 3.5 m 81 3
Table 1: Patient demographics
*Underwent two MR exams four months apart
na=not available
m=male
f=female
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MR imaging
Scout images were made in three orthogonal directions to position MRI slices for 
subsequent scans. The transmit frequency was set on the water resonance and the 
transmitter voltage was adjusted to the load. 
All imaging was performed in the transversal plane centered on the middle femur 
for the thigh, or the largest circumference for the leg. 
T1 weighted spin echo (SE) MR images were acquired first (field of view (FOV) 
175x175mm; base resolution 384; repetition time (TR) 530ms; echo time (TE) 
16ms; slices 23; slice thickness 4mm; gap 0.4mm). 
Turbo Inversion Recovery Magnitude (TIRM) images were collected with an 
inversion time (IT) to null the fat signals (FOV 175x175mm; base resolution 256; 
TR 4000ms; TE 41ms; IT 220ms; slices 23; slice thickness 4mm; gap 0.4mm) to 
visualize edema21-23. To avoid inflow artifacts from venous and arterial blood, 
saturation bands were placed above the upper and below the lower slice24. 
Subsequently, multi SE MR images (qT2-MRI) were acquired (FOV 175x175mm; 
base resolution 256; TR 3000ms; 16 equally spaced TE’s 7.7-123.2ms; slices 5-8, 
limited by specific absorption rate; slice thickness 6mm; gap 9mm). 
Phosphorus MR spectroscopic imaging (31P MRSI)
A 31P quadrature insert surface coil covered the quadriceps muscles of the thigh, 
and for the leg measurements a circularly polarized half volume 31P coil covered 
the calf musculature. A 3D 31P MRSI dataset was acquired after imaging (FOV 
150x150x200mm; matrix-size 14x14x8 quadriceps/ 10x10x8 calf, TR 1000ms; 
BIR45 adiabatic pulse for excitation; 12 averages; weighted k-space acquisition; 
nominal voxel volume 8.6ml quadriceps/16.6ml calf). Datasets were interpolated 
to a matrix size of 16x16x8. 
Data analysis
MR imaging
Each of the investigated muscles (see figure 1) was analyzed separately. 
T1weighted images were scored for fatty infiltration using the four grade scale of 
Lamminen25, by one experienced musculoskeletal radiologist (J.W.J.R). When a 
different score was awarded to the proximal and distal images the average score 
was used. 
Muscle area was assessed by drawing regions of interest (ROI’s) for every muscle 
on the center slice of the T2weighted MRI. Fat and muscle fractions were 
quantified from the qT2-MRI images as described earlier8. Note that normal fat-
fraction for healthy muscle does not exceed 10%26. This method is not suitable 
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when edema is present, as it will affect the tissues transverse relaxation properties. 
In those cases, T1 signal intensity (SI) and TIRM SI of the individual muscles were 
quantified by carefully drawing ROI’s in ImageJ (http://rsb.info.nih.gov/ij/) and 
normalized to bone marrow SI. 
To assess natural progression fat-fraction differences were normalized to a period 
of one year for every patient (for every muscle) by dividing these fractions by 
the exact number of days between the baseline and follow up measurement, 
multiplied by 365.25.
31P MRSI
From the middle slice of the 3D-MRSI dataset with the largest circumference, 
representative voxels were assigned to a specific muscle according to the 
corresponding T1weighted image overlaid with the MRSI grid. Only spectra with a 
sufficient signal-to-noise-ratio (SNR) (Cramer Rao Lower Bound (γATP) < 30%) were 
included for further analysis. 
Free induction decays were zero-filled to double the number of points and 
apodized by 8Hz with a Lorentzian line shape and manually phased using jMRUI 
4.027. Peak areas were obtained from inorganic phosphate (Pi), PCr (fitted to 
a Lorentzian line shape), and ATP (fitted to a Gaussian line shape), using the 
AMARES algorithm28 with prior knowledge on the relative line width, frequency 
and amplitude.
Metabolite ratios: PCr/ATP and Pi/ATP were evaluated to avoid coil profile 
variations. The pH was calculated from the Pi-PCr frequency shift29. The value of 
each parameter was averaged for all analyzed voxels in one muscle and this value 
was used for further analysis. 
Statistics
Statistical analyses were performed with Prism 5.0 (GraphPad Software, San 
Diego, California, USA). Non-parametric one-way-ANOVA (Kruskal-Wallis test) 
was used to investigate differences in the average fat-fraction between muscles, 
with Dunn’s Multiple Comparison Test as post-hoc test. One-tailed correlation 
analyses were performed between fat-fraction and patients’ age, duration of 
disease, radiological score, Ricci-scores, maximum voluntary force, PCr/ATP, Pi/
ATP, and pH.  Linear regression analysis was used to assess the distribution of fatty 
infiltration over the length of the muscle. Outcome parameters in this analyses are 
the slope of the line, indicating the direction of fatty infiltration over the length 
of the muscle, and the coefficient of determination (R2), indicating to what extent 
fat-fraction increases or decreases linearly over the length of the muscle. One-
way ANOVA was used to investigate dependence of fat-fraction progression on 
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initial muscle fraction. T1 SI difference was compared between muscles normal 
and hyperintense TIRM images with a one-tailed t-test, and correlation was 
investigated with linear regression. 
Figure 1: Typical transversal T1 weigthed and TIRM MR images of FSHD patients. (A) Transverse T1 
weigthed image of the thigh of a male FSHD patient (age 38), showing fatty infiltration (hyperintense 
signal) in the semimembranosus and semitendinosus muscles. (B) Transverse T1 weighted image of 
the leg of a male FSHD patient (age 66 year). Fatty infiltration of the soleus muscles is clearly visible. 
(C) Transverse T1 weighted image of the thigh of a 39-year-old male FSHD patient. (D) Corresponding 
TIRM image. The semi-membranosus is clearly fat infiltrated (grey striped arrow), this results in a nulled 
signal on the corresponding TIRM image. In contrast, the vastus lateralis and vastus intermedius show 
hyperintense signal in the TIRM images (white arrows) reflecting edema or inflammation. 
The different muscles in the thigh (Figure 1.A) and calf (Figure 1.B) are indicated by the following 
abbreviations: rectus femoris (RF), vastus lateralis (VL), vastus intermedius (VI), vastus medialis (VM), 
sartorius (S), adductor longus (AL), adductor magnus (AM), gracillis (G), semi membranosus (SM), semi 
tendinosus (ST), biceps femoris long head (BFL) and biceps femoris short head (BFS), tibialis anterior 
(TA), extensor digitorum, longus (EDL), peroneus brevis (PB), tibialis posterior (TP), soleus medialis 
(SOM), soleus lateralis (SL), gastrocnemius medialis (GM) and gastrocnemius lateralis (GL).
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Results 
Muscular fat infiltration, edema, clinical grading and muscle strength in FSHD 
Fat infiltration in skeletal muscles is visible as hyperintense areas on T1 weighted 
MR images (Figure 1A-C). This may be accompanied by edema, which can be 
identified independently from fatty infiltration by TIRM images (Figure 1D). In 41 
FSHD patients we investigated 446 leg muscles, of which 4.3% showed edema, 
which was mostly present in the quadriceps muscles.
The quantitative assessment of muscular fat-fraction revealed that 262 of the 
remaining 427 muscles were normal or mildly fat infiltrated (<25% fat-fraction), 54 
were intermediately fat infiltrated (fat-fraction between 25% and 75%) and 111 
muscles were severely infiltrated (>75% fat infiltration). A fat-fraction distribution 
plot resulted in a typical hourglass shape (Figure 2A). Significant differences were 
observed in average fat-fractions of thigh muscles (p < 0.01), in particular the 
semimembranosus had a significant higher fat-fraction than the vastus lateralis and 
vastus medialis (Figure 2B). 
Figure 2: Distribution of naturally occuring fat-fraction of the thigh muscles of a large cohort of FSHD 
patients. (A) Fat-fraction distribution over all muscles. Fat-fraction of 0% signifies 100% muscle, 1 
indicates 100% fat. Muscles with an intermediary fat-fraction (between 25% and 75%) are observed, 
in ~13% of the investigated muscles. (B) Involvement of individual thigh muscles in FSHD. Average 
fat-fraction of 36 patients. Error bars (SEM) reflect the high variability in this fraction between patients. 
The SM appears to be the most affected muscle of the upper leg, having a significantly higher average 
fat-fraction (54%±41%) compared to the VL or VI (20%±29%, 20%±27%, respectively). Note that 
fat-fractions are not Gaussian distributed therefore reporting only mean±error values is not a good 
representation of the data. 
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Average fat-fraction correlated positively with patients’ age (p<0.05, R2=0.15) 
(Figure 3A) and FSHD duration (p<0.0001, R2=0.54), (Figure 3B). Slopes of the 
correlations were not significantly different between muscles (Supplemental 
Figures S1 and S2). The average yearly increase in fatty infiltration was 0.8±0.4% 
for age and 1.9±0.3% for FSHD duration. The average fat-fraction showed a 
strong correlation with radiological scores (p<0.0001, R2 = 0.70) (Figure 3B) and 
with overall clinical Ricci score for FSHD severity (p<0.0001, R2=0.90) (Figure 
3C). The fat-fraction deviated from normal at Ricci score 2 (a subclinical event as 
this score excludes leg muscle involvement) and further increased at higher Ricci 
scores. Muscle fraction multiplied by the muscle area significantly correlated with 
muscle strength for the quadriceps and hamstring (p <0.0001, R2 = 0.57) (Figure 
3D). 
Figure 3: Correlation of fat or muscle fraction, determined by quantitative MRI, with clinical scores. 
(A) Correlation between age of the patient and average fat-fraction of the thigh (p<0.05, R2=0.15).   
(B) Fat-fraction highly correlates with the radiological Lamminen score of the corresponding muscle 
(p<0.0001, R2=0.70). (C) Quantitative fat-fraction of lower limb correlates with patients Ricci score 
(p<0.0001, R2 = 0.90). Fat-fraction starts to increase above normal levels at Ricci score 2. The high 
standard deviation depicted in the error bars signifies the large variation in fat-fraction determined in 
the limb and the appointed Ricci score. (D) Correlation between muscle fraction (1-fat-fraction) and 
force of quadriceps and hamstring muscle groups (p<0.0001 and R2= 0.76).
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Intramuscular fat distribution 
Visual inspection of MR images revealed that the fat-fraction was often not evenly 
distributed over the length of the muscle (Figure 4). Muscle with an intermediate 
fat-fraction showed the steepest fatty infiltration gradient over the length of the 
muscle (7±1% cm-1, mean±SEM). This value was significantly higher compared to 
muscles that were normal or mildly fat infiltrated (1.3±0.3% cm-1, p <0.0001) and 
those that were heavily infiltrated by fat (1.1±0.1% cm-1, p <0.0001). Overall fat-
fraction rose from proximal to distal.  
In one subject we performed compete thigh imaging in the three dimensions 
to show that the fatty infiltration gradient truly is in the proximo-distal direction 
proving that the fatty infiltration does not increases towards the tendons (Figure 
5).
Natural progression of fatty infiltration
The natural progression of fatty infiltration was investigated for 85 muscles 
of eleven patients. An average increase in fat-fraction of 5.4%±12% per year 
was observed. In intermediately affected muscles (n=12) the progression of 
fatty infiltration was much faster (18±15% per year) as compared to heavily fat 
infiltrated muscles (0.0±10% per year, n=20) and to normal to mildly infiltrated 
muscles (4.3±10% per year, n=53). Natural progression in fat infiltration depended 
on the initial muscle fraction (p< 0.01) and appeared to increase from distal to 
proximal (Figure 4).
Six muscles, in two patients, showed hyperintensity on the baseline TIRM images, 
indicating edema. The T1 SI difference between baseline and follow up exam, 
representing fat infiltration, was significantly different in muscles with hyperintense 
signal on baseline TIRM images compared to TIRM normal muscles (n = 14) of 
the same patients (p<0.01) (Figure 6). Linear regression analysis showed a trend 
between the TIRM SI and the difference in T1 SI (p<0.1, R2=0.1). 
High-energy phosphate metabolites
Analysis of phosphate metabolites by 31P MRS revealed that the PCr/ATP ratio 
correlated with the fat-fraction of the specific muscle (quadriceps p < 0.05, R2 = 
0.06, calf p<0.01, R2=0.33). This PCr/ATP ratio is significantly decreased in the 
intermediately fat infiltrated muscles compared to muscles with a normal fat-
fraction (p<0.05), but was not further decreased in muscles with a high fat-fraction 
(Figure 7A). The PCr/ATP ratio also correlated with muscle force (p<0.001, Figure 
7B). 
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Figure 4: Intramuscular distribution and progression of fatty infiltration. Transveral T1 weighted 
images at different positions of the thigh of a FSHD patient. Baseline measurement (left panels) 
reveals an uneven distruibution over the length of the muscle with an increasing fat infiltration from 
proximal (top) to distal (bottom), especially prominent in the VM, VI, AM. This fatty gradient was 
largest in intermediate fat infiltrated muscles, as was shown by the linear regression analyses. These 
intermediately fat infiltrated muscles also showed the largest increase in fatty infiltration over time. 
From the follow-up measurement (right panels) it is clear to see that fat is increasing distally.  AM = 
adductor magnus; BFL = biceps femoris long head; VI = vastus intermedius; VL = vastus lateris; VM = 
vastus medialis.
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Figure 5: A 61-year-old-man FSHD shows increasing fat infiltration towards the knee. He was diagnosed 
in 1992 and is still able to walk independently. 
Replacement of muscle-tissue by fat is characteristic for muscular dystrophies, but the initiation point 
of fatty infiltration remains obscure. A possibility is that it starts at the tendons and spreads from both 
extremities towards the middle of the muscle. However this 3D-T1weighted thigh MRI proves that 
fatty infiltration in FSHD starts distally. The coronal oblique plane (A), quadriceps angled, shows a fatty 
infiltration gradient in the vasti (red arrows). The sagital oblique plane (B), hamstrings angled, shows an 
intact gracillis (green arrows) and a fatty infiltration gradient in the biceps femoris (blue arrows). Axial 
images show that fatty infiltration increases in craniocaudal direction (C-D-E). 
This pattern is unusual and may be FSHD specific. It raises fundamental questions about dystrophic 
mechanisms and biological differences between muscles.
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Figure 6: The presence of edema, as identified by TIRM imaging, correlates with increased fatty 
infiltration, as reflected in changes in T1 weighted images. (A) TIRM and T1 weighted images of a 76 
year-old male FSHD patient. (B) TIRM and T1 weighted images of a 39 year-old male FSHD patient. 
(A-B.1) VL(*) and VM(**) muscles of two FSHD patients show hyperintensity on TIRM images, indicating 
edema. (A-B.2) Baseline T1 weighted images. (A-B.3) Follow-up T1 weighted images showing an 
increase of fatty infiltration after about 4 months in the VL(*) and VM(**) muscles. (C) SI difference 
between baseline and follow-up T1 weighted images is significantly different in TIRM hyperintense 
FSHD muscles (N=6) compared to TIRM normal FSHD muscles (n=14) (p<0.01).
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Figure 7: High-energy phosphates in the different stages of fatty infiltration and correlation with 
muscle force. (A) Representative phosphorous MR spectra of VL muscle of FSHD patients, upper with 
a normal fat-fraction, lower with a high fat-fraction. (B) PCr/ATP decreases with fat-fraction (mean±SD). 
In intermediately fat infiltrated muscles the PCr/ATP is already decreased significantly from 4.15±1.00 
to 3.57±0.88. Completely fat infiltrated muscles do not show a further decrease of this ratio. (C) 
Significant correlation between PCr/ATP and muscle strength (p<0.001, R2=0.29). Pi = inorganic 
phosphate; PCr = phosphocreatine; ATP = adenosine triphosphate.
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Discussion
In this study we identified three distinct phases of fat infiltration in lower limb 
muscles of FSHD patients by quantitative MR. An analysis of the average fat-
fraction for all individual muscles uncovered an hourglass pattern of many 
muscles with either very low or high fat, and few muscles with an intermediate 
fat-fraction. This quasi-binary distribution has not been reported for other 
muscular dystrophies7 and may be FSHD specific. The intermediate phase is most 
characteristic, showing a relative steep fat gradient over the length of the muscles, 
an altered energy metabolism and rapid progression of fatty infiltration.
 For other dystrophies average values of all subjects or muscles are often 
presented, which obscures the presence of a specific distribution. The average 
fat-fraction as calculated over all investigated muscles in this study (30%±10%), 
actually only was present in 36 out of 427 muscles. Fat-fractions were highest 
in the semi membranosus, semi tendinosus and adductor muscles as has 
been previously described by Wattjes et al.21. The vastus muscles were largely 
preserved.   
We found that in leg muscles the intramuscular fat-fraction increased linearly from 
proximal to distal, as was also observed in a pilot study of only the lower leg8. The 
steepest fat gradient occurred in the intermediate affected muscles indicating 
that these muscles are progressing towards a complete fat infiltrated state. This 
interpretation is supported by the follow-up measurements, which revealed that 
intermediate affected muscles were most prone to increase their fat-muscle ratio. 
In these muscles the average increase of this ratio was about 10% in four months. 
This may seem fast for a disease that is characterized by slow progression, but 
we observed it in only a relative small fraction of muscles. The quasi-binary fat 
distribution of muscles in FSHD patients mentioned above also indicates that 
relative rapid transitions occur. Moreover, a sudden disease progression within 
individual muscles is in accordance with the often reported observation in FSHD 
patients of periods of rapid deterioration of single muscles or muscle groups, 
interrupting long stable periods30,31. In some cases the lower performance of a 
single muscle may be compensated by unaffected synergistic muscles, which 
would clinically mask its dysfunction32,33. Assuming that replacement of muscular 
tissue by fat occurs at a constant rate after entering this intermediate phase, 
fat replacement of entire muscles will, on the average, be completed within 
approximately three and a half years. This can be relevant for prognostication and 
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monitoring therapy effectiveness in FSHD.  There is no report on fat gradients 
over the length of muscles in other neuromuscular disorders, which may be FSHD 
specific. Recently, a muscular fatty content gradient was also found in inherited 
poly-neuropathy, but this was not associated with disease progression34.
The low percentage of muscles involved in a rapid progression towards complete 
fatty infiltration indicates that this process is triggered by an infrequent event. 
The nature of this event is unknown, but the initial relatively high distal level of 
fatty infiltration and the differences between muscles suggests a local origin. This 
is in agreement with findings that only 0.1% of muscle nuclei express DUX4 in 
FSHD patients35. A recent paper by Tassin and colleagues36 describes a model 
of initiation and propagation of a transcriptional cascade, which provides an 
elegant explanation for our observation of a gradient of fatty infiltration and fast 
progression in intermediate fat infiltrated muscles. In this model the activation 
of the DUX4 gene in (one or) few myonuclei yields DUX4 protein molecules that 
diffuse into the cytoplasm towards neighboring nuclei where they activate target 
genes, which causes expansion into a transcriptional cascade of deregulation. 
Because of the multinucleated nature of myofibers this model predicts a gradient 
of deregulation over the length of muscles. The amplification of DUX4 gene 
activation into a transcriptional cascade may also explain the fast progression 
observed in the intermediate fat infiltrated muscles. Preferential involvement of 
particular muscles (e.g. semi membranosus) and distal initiation may hide clues 
towards the initial DUX4 gene activation trigger. Our finding that MR-visible fat 
content increases more in the case of initial edema supports the involvement 
of inflammation in early disease onset, as TIRM positive muscles are associated 
with muscle inflammation21-23,37-39. However, whether inflammation is cause or 
consequence of DUX4 transcription in the initiation process remains unclear. 
The correlation between increased fat-fraction and lower strength of skeletal 
muscles is coherent with the loss of muscle mass and also explains the (weak) 
relation with the age of the patients.  Clinical severity scores (Lamminen25 and 
Ricci19) strongly correlated with fat-fraction, but abnormal high fat-fractions were 
also present in lower limb muscles without clinical symptoms, as was observed in 
patients with Ricci score 2 (excludes lower limb involvement). Thus, imaging fatty 
infiltration is a potential tool to predict clinical muscle affliction32,33. The extent of 
edema in our study (4.3%) is somewhat lower than reported in two recent FSHD 
studies, that however, included more muscles per patient and more severely 
affected patients23,40.
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The lower PCr/ATP ratios observed in intermediately fatty infiltrated muscles 
suggest an early change in high-energy phosphate metabolism in disease 
development. Lower steady state PCr/ATP ratios were also found in muscles of 
Becker and Duchenne patients10,41. This may represent a lower cellular (phospho)
creatine pool due to a lower energy state. Alternatively, it may represent a 
change in fiber type composition, if the fraction of oxidative fibers, which have 
lower PCr/ATP ratio’s42,43, increase due to preferred involvement of type II fibers. 
This is supported by histological findings of biopsies, showing more dominant 
type I fibers among the remaining fibers in FSHD affected muscles44 and is also 
congruent with the correlation between PCr/ATP and muscle force.  
Taking muscle biopsies remains the gold standard to examine muscular 
dystrophies, but this is invasive, painful, restricted to a limited number of biopsy 
sites and only provides focal information. As observed in the present and a 
previous study8 fatty infiltration is very heterogeneous, both between and within 
muscles, which demonstrates the need to know in advance which (part of a) 
muscle is affected, to acquire representative tissue. Our study indicates that MRI 
guidance in taking muscle biopsies is needed. Other common imaging techniques 
have disadvantages, such as radiation exposure in computer tomography, or 
poor signal to noise and limited penetration depth in ultrasound.  In clinical trials 
muscle strength is often assessed to evaluate treatment effects, but this may show 
a placebo effect45. Muscular fat-fraction determined by MRI does not involve a 
placebo effect.
 
A limitation of our study was the lack of including a component for the presence 
of edema in the T2 analysis. However, we identified muscles with edema by TIRM 
and excluded the very small fraction of edematous muscles from this T2 analysis. 
Progression of fatty infiltration in these muscles was then derived from T1 images. 
Furthermore, we chose to investigate lower extremity muscles in these patients 
even though FSHD is a disease known to first involve the facial and scapular 
muscles. However, for this study we aimed for the highest image quality, which 
could be achieved with a dedicated coil for the lower extremity. To compare 
different disease phases we had to introduce fat-fraction cut-off values, for which 
we chose 25% and 75% of fatty infiltration. Shifting these values by ±5% did not 
change the main results of this study.  
In conclusion, this study established fat-fraction as assessed by MR imaging as 
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an objective quantitative and sensitive biomarker for muscular affliction in FSHD, 
detecting even subclinical muscle involvement. This MR biomarker may serve 
to predict disease progression, to guide biopsies and to evaluate treatments to 
preserve or improve muscle performance. Importantly, in these applications the 
intramuscular fat distribution may have to be taken into account. Our data suggest 
a specific sequence of events that leads towards full muscle pathology in FSHD, 
in which muscles first progress from normal to being distally fat infiltrated, with an 
altered metabolic profile, after which fat rapidly infiltrates the whole muscles. This 
process of disease unfolding may direct new treatment strategies.
Acknowledgments: We thank Rob J.W. Arts for helping with data processing and 
Jos IJspeert for performing the force measurements. 
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Abstract
Background: Ultrasound and MR imaging are non-invasive methods that can be 
performed repeatedly and without discomfort. In the assessment of neuromuscular 
disorders it is unknown if they hold complementary information. In this study we 
tested this for patients with facioscapulohumeral muscular dystrophy (FSHD).
Methods: We performed quantitative muscle ultrasound (QMUS) and quantitative 
MRI (QMRI) of the legs in 5 men with FSHD. 
Results: The correlation between QMUS determined z-scores and QMRI 
determined fat-fraction and T1 signal intensity (SI) was very high. QMUS had a 
wider dynamic range than QMRI, whereas QMRI could detect inhomogeneous 
distribution of pathology over the length of the muscles. 
Discussion: Both QMUS and QMRI are well suited for imaging muscular dystrophy. 
The larger dynamic range of QMUS can be advantageous in follow-up of 
advanced disease stages, whereas QMRI seems preferable in pathologies such 
as FSHD that affect deep muscle layers and show inhomogeneous abnormality 
distributions.
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Introduction
In many neuromuscular disorders there is a need for biomarkers to help 
characterize the disease process and monitor the effects of treatment. To monitor 
changes in muscle tissue over time, non-invasive methods such as muscle imaging 
are preferable over muscle biopsy. The most common imaging techniques in 
muscle disorders are computerized tomography (CT), magnetic resonance imaging 
(MRI), and ultrasound scanning (US). Of these, CT has become largely obsolete 
because of the associated radiation dose, which is especially problematic in 
children and in case of repeated measurements. 
MRI visualizes superficial and deep muscle tissue equally well1. It can detect fatty 
infiltration on T1- and T2-weighted MR images. On T2-weighted images in which 
the fat signal is nulled, such as in STIR and TIRM imaging, signal hyper-intensity 
suggests the presence of edema and/or inflammation2,3. Fibrotic tissue has no 
signal intensity on conventional MRI and is therefore visualized as a black spot.
Potential disadvantages of MRI are the limited availability, claustrophobia, 
costs, and the necessity for sedation or anesthesia in young children. In the 
characterization of neuromuscular disorders by MRI, muscles are usually graded on 
a semi-quantitative scale based on the appearance of the T1-weighted images4-6. 
However, more objective MR methods to assess disease severity are available, 
such as those that quantify the amount of fatty infiltration7,8. 
Muscle ultrasound is another non-invasive technique that visualizes normal 
and pathological tissue in neuromuscular disease9,10. Using quantitative muscle 
grey scale analysis, infiltration of fat, fibrous tissue, and inflammation can be 
determined objectively, as they increase muscle echo intensity11. Quantitative 
muscle ultrasound (QMUS) using grey scale analysis makes use of reference 
values for each muscle corrected for age and weight-related changes in echo 
intensity (EI) and the innate differences between individual muscles. Muscle 
pathology, including muscular dystrophy, commonly leads to increased muscle 
echo intensity as normal muscle tissue gets replaced by and interspersed with 
fat and fibrosis. QMUS has high predictive value in screening for neuromuscular 
disorders in children12 and adult disorders such as amyotrophic lateral sclerosis13. 
It was also found to be sensitive to changes due to disease progression over time 
in Duchenne muscular dystrophy14. QMUS is a patient-friendly technique because 
of its non-invasive nature and can be performed bedside within a limited amount 
of time (e.g. within 30 minutes for most protocols). The main drawback of QMUS 
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is that it is only suited for displaying superficial muscle layers. This is because 
attenuation, i.e. a progressive reduction in amplitude of the ultrasound beam, 
occurs as it travels further through tissue. The amount of attenuation caused by 
overlying tissue layers varies between subjects. Therefore, no reliable reference 
values can be established for the deeper muscle. In addition, pathologic changes 
in superficial layers may cause loss of all ultrasound energy from the beam before 
it even reaches the deeper parts of a muscle (Figure 1). Furthermore US is not able 
to distinguish between abnormal signal intensities due to fatty infiltration, fibrosis 
or inflammation. 
Facioscapulohumeral dystrophy (FSHD) is one of the most common muscular 
dystrophies15. It is an autosomal dominant disorder characterized by a deletion 
of a 3.3 kb tandem repeat, D4Z4, on chromosome 4q35 in more than 95% of 
patients (FSHD type 1). In some cases (FSHD type 2), D4Z4 chromatin relaxation 
and stable DUX4 expression occur in the absence of D4Z4 array contraction15. 
FSHD types 1 and 2 are characterized clinically by asymmetric, descending 
involvement of muscles in the face, upper extremity, trunk, and lower extremity 
regions, and the severity varies widely16. In FSHD it has been shown that fat-
fraction (Ffat) determined by quantitative T2-MRI (qT2-MRI), of the muscle 
correlates with clinical strength and is sensitive enough to detect disease 
progression7,17. These results were corroborated in a recent study by Friedman and 
co-workers, who also showed that muscle edema is common in FSHD patients and 
that edema may be useful as an intermediate biomarker for disease progression 
or treatment effects18. In addition, it was recently shown that the distribution of 
pathology along the muscle length varies considerably in FSHD patients17. There 
are no muscle ultrasound studies in FSHD patients yet. 
The validity of muscle ultrasound versus MRI has been established for 
measurements of muscle thickness, length, and cross sectional area for several 
muscles in resting and contracted states19-22. Comparisons have been made 
between MRI and US in the fields of cancer detection23,24. Although both MRI and 
US have seen significant developments in the past decade to provide potential 
biomarkers for neuromuscular disorders, no studies have been performed yet 
comparing the 2 techniques head to head in this context. 
We performed this study to compare QMRI and QMUS in depicting muscle 
pathology, with respect to changes in muscle architecture and different stages of 
dystrophic pathology. In particular we explored the utility of the combination of 
MRI and US to assess the quadriceps muscle in 5 adult men with FSHD type 1. In 
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this way we compared technical advantages and challenges of 1 technique versus 
the other, evaluated whether their results overlap, and if they hold complementary 
information in studying muscle pathology. This pilot study was part of a larger 
project that evaluates the effects of training in FSHD patients using MRI as a 
biomarker25. 
Figure 1: Ultrasound (A,B,D,E) and T2-weigthed MRI images (C,F) of the right leg of 2 FSHD patients 
(#1 and #3). Single asterisk indicates the rectus femoris muscle, and double asterisks indicate the 
vastus lateralis muscle. Top panels (A-C): normal echo intensity and MRI in patient #1. Bottom panels 
(D-F) abnormal echo intensity (z-score 8.64) of the rectus femoris muscle(D), signifying complete fatty 
infiltration as is seen clearly by the high intensity signal from the MRI image, and less abnormal vastus 
lateralis muscle. 
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Methods
Patients
Five men with FSHD of varying ages (34 – 61 years) and disease severity (Ricci 
score: 2 – 4) were included in the study; demographics are shown in table 1. All 
patients had genetically proven FSHD1, and clinical severity was assessed with 
the Ricci score, a 10-point clinical severity scale (0.5-5), with 0.5 indicating only 
facial weakness, and 5 indicating wheelchair dependence26. Muscle strength of 
the quadriceps was measured in kg using a fixed dynamometer27. One patient 
was obese with a BMI of 33.6, but his subcutaneous fat layer thickness over 
the quadriceps muscle was 8 mm at maximum and did not cause abnormal 
attenuation of the ultrasound beam. All measurements were done in accordance 
with the Helsinki Declaration. Our institutional ethics committee approved the 
study protocol, and all patients provided written informed consent. 
Magnetic resonance imaging
MRI exams were performed on a 3 Tesla MR system (TIM Trio, Siemens, Erlangen, 
Germany). Patients were positioned feet first supine in the bore of the magnet. 
Images were acquired by a home-built proton birdcage coil (inner diameter of 
25 cm) placed around the upper leg. The frequency was set to the water proton 
resonance, and the transmitter voltage was adjusted to match the load of the coil.
A fish-oil capsule was placed as a marker at two-thirds of the distance from the 
anterior superior iliac spine (ASIS) to the superior lateral aspect of the patella 
for accurate positioning of the imaging slices. Scout images were made in 3 
orthogonal directions to position imaging slices for subsequent scans. 
Transverse T1-weighted MR images were acquired around the marker to cover 
100.8 mm around the center of the femur (field of view 175 x 175 mm; base 
resolution 384; repetition time 530 ms; echo time 16 ms; slices 23; slice thickness 
4 mm; slice gap 0.4 mm; acquisition time 3:55 minutes). Average signal intensity 
of the regions of interest (T1 SI) was used for further analysis. 
Turbo Inversion Recovery Magnitude (TIRM) was acquired from the same location 
to check for the presence of edema or inflammation. The inversion time was 
selected to null the fat signals (field of view 175 x 175; base resolution 256; 
repetition time 4000 ms; echo time 41 ms; inversion time 22 ms; slices 23; slice 
thickness 4 mm; slice gap 0.4 mm; acquisition time 3:22 minutes). Saturation 
bands28 were placed above the upper and below the lower slice to avoid inflow 
artifacts from venous and arterial blood. 
Subsequently, multi spin echo MR images were acquired from the same location 
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(field of view 175 x 175; base resolution 256; repetition time 3000 ms; 16 equally 
spaced echo time 7.7 - 123.2 ms; slices 5-8, limited by SAR; slice thickness 6 mm; 
slice gap 9 mm; acquisition time 8:05 minutes) to allow for quantitative assessment 
of fat and muscle tissue distribution. Images were stored off-line as DICOM 
and analyzed using a custom-made data analysis program in IDL (ITT Visual 
Information Solutions, Boulder, USA, v6.2). ROIs were drawn on the vastus lateralis 
(VL) and the rectus femoris (RF) carefully to avoid blood vessels. Only these 2 
muscles were selected, since they were also the subject of the US examination. 
The method was explained extensively by Kan et.al.7 Every image slice was 
analyzed separately (Ffat slice). 
Performing the entire MR protocol took about 30 minutes, including patient 
positioning in the scanner. An additional 30 minutes was necessary to quantitate 
and analyze all the images. 
Quantitative muscle ultrasound
Muscle ultrasound was performed using a Philips IU22 ultrasound scanner (Philips 
Healthcare, Eindhoven, the Netherlands) and a 8-4 MHz broadband linear 
transducer, which has an axial resolution of around 0.3 mm. Machine settings 
have been determined empirically in our lab to achieve muscle ultrasound images 
in which healthy muscle and subcutaneous tissue appeared relatively black with 
strong reflections of fascia and bone, using a gain of 59%, compression of 55%, 
the time gain compensation witches in neutral position, an imaging depth of 6 
cm, and the image focal zone at a depth of 3 cm with a broad range from 0-6 
cm. No additional image enhancement settings (e.g. Sono-CT and Xres) were 
used. System settings were available through a preset and kept constant for every 
quantitative muscle ultrasound measurement in our lab, ensuring compatibility 
between measurements. Patients were examined supine with their arms and legs 
extended (as much as possible in case of contractures) and their muscles relaxed. 
QMUS measurements were performed of the VL and RF. All scans were made in 
the transverse plane with a standard transducer location corresponding to the 
muscle belly at the following anatomical sites that reflect maximal muscle belly 
diameter29: the RF halfway along the line from the ASIS to the superior middle 
aspect of the patella and the VL at two-thirds of the distance from the ASIS to the 
superior lateral aspect of the patella (Figure 2). A generous amount of contact gel 
was used to minimize the required pressure of the transducer on the skin.
For each muscle, 3 consecutive measurements were made to minimize variation 
in echo intensity during analysis. The screen images of these measurements were 
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stored offline in DICOM format. As oblique scanning angles can lead to incorrect 
muscle thickness and echo intensity measurements, it was avoided by adjusting 
the angle of the probe until the best bone echo was obtained in every image. The 
captured images were analyzed offline for echo intensity by means of computer-
assisted grayscale histogram analysis using custom software (Qumia) developed 
at our center. In each of the stored muscle images, a region of interest (ROI) was 
selected manually. The ROI was defined as the region that included as much 
muscle mass as possible without bone and fascia. From the selected region the 
mean muscle echo intensity of the 3 images was calculated based on a histogram 
analysis9. Raw muscle echo intensities were next converted to z-scores, i.e. the 
number of standard deviations from the mean score for gender, age, and weight 
using previously established reference values30; these z-scores were used for 
further analysis.
Performing the QMUS protocol took 10 minutes.  Quantification and analysis of 
the images took an additional 5 minutes.
 
Slice matching
The anatomical location at which the ultrasound measurement of the VL was 
performed was equal to the location of the MR marker. The MR slice showing the 
marker was therefore assigned as the slice corresponding to the US slice. To find 
the MR slice corresponding to the US slice of the RF, a calculation was made to 
convert length in mm into a number of slices. US of the RF was performed halfway 
along the line from the ASIS to the superior middle aspect of the patella. The 
distance from this location to the MR marker was divided by the distance between 
Figure 2: An MR marker was placed at one-third the 
distance from the anterior superior iliac spine to the 
superior lateral aspect of the patella. From this location 
the QMUS of the VL is taken, and the QMRI slice showing 
the marker is the matched MR slice. The QMUS from the 
RF is taken at one-sixth the distance from the anterior 
superior iliac spine to the superior lateral aspect of the 
patella, higher corresponding to the position of the MR 
marker. By taking into account the distance between the 
MR slices the corresponding QMRI slice is matched.
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the MR slices (15 mm multi spin echo images, 4.4 mm T1 images), to calculate 
which slice corresponded to the echo slice of the RF (Figure 2).
To study the sensitivity of “single slice” QMUS for spatial variation over the length 
of the muscle the z-score was correlated to: 1) the fat-fraction of the slice (i.e. Ffat 
slice) at the same location as the US was taken and 2) the fat-fraction averaged 
over the length of the muscle (i.e. Ffat average). Furthermore, the correlation 
between z-score and 3) the slice-matched T1 SI was studied.
Statistical analysis
All statistical analyses were done using Graphpad Prism 5.0 (Graphpad Software, 
San Diego, California, USA). Because of the skewed distribution of the Ffat 
(maximum score of 1 and minimum of 0) and ultrasound z-scores (with scores 
below 0 all indicating normal muscle) a Spearman Rho analysis was used to 
calculate the correlations between QMUS z-score and the QMRI parameters Ffat 
slice, Ffat average, and T1 SI. Because of the sigmoid shape of the raw results 
when comparing QMUS parameters with QMRI parameters we attempted to fit 
the relation between the 2 using a Boltzmann function (Figure 3). As the Ffat has 
a value between 0 and 1, the variable Top in the equation was set equal to 1 and 
Bottom to 0. As the upper value of the T1 SI is theoretically limitless, Bottom was 
set to 0 and Top had no restriction for this parameter. V50 gives the z-score at 
which the fitted curve is halfway between top and bottom (i.e. 0.5 for Ffat), and 
slope describes the steepness of the curve, with a larger value denoting a more 
Figure 3: Basic Boltzmann sigmoid 
function and corresponding 
mathematical equation. The 
function is characterized by a 
plateau top and bottom with a 
characteristic V50 value describing 
the point where the x value is 
exactly between the top and 
bottom value and slope indicating 
in what range the transition 
between top and bottom occurs. 
In our case the V50 denotes which 
z-score of QMUS signifies 50% 
fatty infiltration of the muscle 
as determined by QMRI, and 
the slope indicates the range 
of z-scores over which the fatty 
infiltration goes from 0% to 100%.
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modest slope. In the context of this study, V50 denotes the tipping point where 
the muscle tissue composition transits from mainly muscle tissue to predominantly 
intramuscular fat. A steeper slope indicates a more abrupt transition of measured 
MRI tissue composition over a more limited range of EI z-scores than a modest 
slope, where the MRI tissue transition is more gradual over a larger range of EI 
z-scores.
To compare the R values of the correlations of “single slice” QMUS and Ffat slice, 
Ffat average and T1 SI, a Fisher r-to-z transformation was used31.
Results
Ten muscles of 5 subjects were investigated by QMRI and QMUS. Demographics 
of the patients and the primary results for EI z-scores, Ffat of the corresponding 
slice, Ffat average, and T1 SI are shown in table 1. Examples of normal and 
abnormal muscle echo intensities are shown in figure 1.
In 1 subject (#4), signs of edema/inflammation were found in the VL muscle on the 
TIRM images (Figure 4). As this makes calculating the MRI fat-fraction unreliable, 
we excluded this muscle from the correlation analysis between QMRI and QMUS. 
One-tailed Spearman correlation analysis showed a good correlation between 
QMUS determined z-score and QMRI determined Ffat average (P = 0.007, R 
= -0.80). The correlation of the z-score with Ffat slice and T1 SI showed similar 
results (P = 0.003, R = -0.65 and P = 0.01, R = 0.72, respectively). Even though 
the coefficients (R) of these correlations vary somewhat, subsequent Fisher r-to-z 
transformation showed no statistical difference, meaning that none of the QMRI 
parameters correlates significantly better with QMUS (and vice versa) than the 
others. 
The relationships Ffat and T1 SI with QMUS z-score could be very well fitted with 
a Boltzmann sigmoidal function (Ffat slice R2=0.996, Ffat average: R2=0.942, T1 
SI R2=0.991), figure 5 and table 2. The Boltzmann sigmoidal function is given 
in figure 3, where x stands for QMUS z-score and y always is the fitted QMRI 
parameter (i.e. , Ffat slice, Ffat average or T1 SI). The steepest slope (i.e. smallest 
value for V50) was found for the relation between EI z-score and T1 signal 
intensity, while the EI z-score plotted against the Ffat average had the shallowest 
curve, indicating a slightly more gradual transition from normal to abnormal 
values.
With respect to the VL muscle with signs of edema/inflammation in subject #4, 
the QMUS z-score of muscle was 2.45, which is most likely slightly abnormal. 
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Figure 4: TIRM (left) and T1 weighted (middle) images of the left thigh of patient #4. Hyper intensities 
are clearly visible on the TIRM image in the vastus lateralis and medialis (white arrows) indicating 
inflammation, in contrast to normal signal intensity on both TIRM and T1w image like the biceps 
femoris longus muscle (grey arrow). Corresponding ultrasound image of the vastus lateralis (double 
asterisk) is displayed in the right panel. 
Ffat average Ffat slice T1 SI
V50 3.1 3.0 2.3
Slope 0.92 0.46 0.12
According to the Boltzmann sigmoidal relationship this corresponds to a fat-
fraction of 33%, which is also slightly abnormal (where the highest values 
encountered in normal subjects are around 15-20%7), while the calculated Ffat 
average for this muscle was 58%. As also shown by figures 5A and B it is clear that 
the QMRI determined muscle-fraction is underestimated in this case. 
In figure 5B one point stands out with a z-score of 1.49 but an average muscle-
fraction of 0.74 (RF patient #1). This was caused by the heterogeneous distribution 
of fatty infiltration along the length of the muscle, figure 6. At the anatomical 
location where the echo was performed, the fat-fraction was 1%. The fat-fraction 
is increasing in the distal direction of the muscle, thus when the fat-fraction of the 
complete muscle is considered, this is higher compared to the exact position of 
the ultrasound measurement. When considering the fat-fraction over the length of 
the muscle in this patient, we observed that for MR slices proximal to the marked 
MR slice the fat-fraction has already risen to 44%. This confirms that a z-score is a 
local measure, and the spatial resolution of QMUS is limited to the beam width. 
Patient #5 had a high Ricci score (4) and low quadriceps strength (14 Kg), however 
Table 2: Best Boltzman Sigmoid fitting parameters between QMUS and QMRI.
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no muscle abnormalities were found either on MRI or US. It seems likely that 
the clinical limitation in this patient was due to his obesity, diabetes, and poor 
cardiovascular condition. 
Figure 6: QMRI determined muscle-fraction over the 
length (slices) of the RF muscle of 1 patient showing large 
variation leading to a lower average muscle-fraction, 
compared to the muscle-fraction at the QMUS measured 
position.
Discussion
We have demonstrated that fatty infiltrated and normal muscle in FSHD can 
be discriminated with both QMRI and QMUS. In addition, we found a good 
correlation between QMUS determined echo intensity z-score and the QMRI 
determined Ffat average, indicating that both techniques can be used to measure 
muscle pathology with similar sensitivities. With progressive pathology, the 
relationship between the echo intensity z-scores and the MRI parameters was not 
linear but followed a Boltzmann sigmoid function, with the steepest slope for T1 
SI and a less abrupt transition from normal muscle to abnormal signal intensity for 
the Ffat average and Ffat slice. This means that, for a linear increase in EI (which, 
somewhat arbitrarily, is called abnormal with z scores ≥ 2), the MRI Ffat average 
and Ffat slice showed a larger dynamic range in the transition from normal to 
abnormal muscle tissue during disease progression than the T1 signal intensity. 
A floor effect for the Ffat MRI parameters was found with increasing US 
abnormality, as Ffat values rose to 100% when the EI z-score reached 5. Similarly, 
a ceiling effect in T1 signal intensity was found with EI z-scores of ≥ 5. Since an EI 
z-score was found up to 8.6 (meaning an EI of 8.6 SD above normal) in the RF of 
patient #3, this suggests that EI z-scores can possibly follow progressive muscle 
pathology for longer than the current MRI parameters can. This maximum value in 
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this study is comparable with previous findings in Duchenne muscular dystrophy, 
where EI z-scores were found up to 9.6 in the oldest, most affected patient14. As 
an MRI fat-fraction of 100% indicates that no more myofibrillar tissue is present in 
the sample, the question remains what the increasing EI signifies and whether it is 
clinical relevant. A possible explanation of a further increasing EI in muscle tissue 
that has been completely replaced by fat and/or fibrosis might be that, even when 
all myofibrils are gone, there can still be progressive changes in the architectural 
organization of the muscle connective tissue (i.e. the “muscle skeleton”). 
A limitation of this study was that for most patients (4/5) the MRI and US exams 
were performed on different days. As FSHD is a progressive disease it is obvious 
that it was preferable to schedule both exams on the same day, but unfortunately 
this was not practically possible for all patients. On average there were 20 days 
between the exams. From a previous longitudinal QMRI study on FSHD we did 
not expect an increase in fat-fraction of more than 3% during that maximum 
period17. Such alterations would not change the correlations between the QMRI 
and QMUS presented here. 
In 1 muscle we found signs of edema or inflammation based on the TIRM image 
results. Even though the EI z-scores for this muscle were in the abnormal range, 
fat-fraction was overestimated by our MRI technique because of the longer T2 
relaxation time of muscle tissue in the presence of edema or inflammation1,11,18,32. 
To use quantitative muscle MRI as an estimate of muscle pathology in the 
presence of edema alternative quantification methods such as the recently 
described Non-Negative Least Squares analysis18 or a Dixon technique8 will be 
required. QMUS echo intensity also reflects alterations due to inflammation or 
edema11, but cannot distinguish this from other, structural muscle pathology. 
Therefore alterations due to edema may be misinterpreted for structural muscle 
pathology. Especially in the study of inflammatory myopathies this is a limitation of 
the technique. Further research is needed to investigate how to deal with inflamed 
muscles using the both imaging techniques. 
In this small patient group (n=5) we encountered 1 patient (#5) who had severe 
clinical symptoms: a Ricci score of 4 and low maximum quadriceps strength. 
However, both MRI and US revealed normal muscle architecture in this patient, 
and the symptoms were most likely explained by his metabolic syndrome. As 
obesity becomes more common it is of importance to be able to discriminate 
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between (muscle) weakness caused by a neuromuscular disorder or a concurrent 
disease. Non-invasive quantitative techniques like QMRI and QMUS help make 
this distinction by determining the degree of muscle degradation. 
As a final point, it is becoming clear that the pathological muscle changes in 
FSHD can show considerable variation along the length of a muscle17. This was 
corroborated by our finding of inhomogeneous distribution of fatty infiltration in 
the RF in patient #1. This is a potential drawback for the currently used QMUS 
protocol, which very well describes the status of the muscle at the location 
measured but does not look for changes at different muscle sites. That explains 
why in the study of patient #1, we did not pick up the fatty infiltration found 
on MRI 6 cm distal to the ultrasound “slice”. This means that for disorders with 
uneven distribution of pathology along the muscle, the sensitivity of a single 
QMUS measurement to detect all pathological changes is limited compared to (Q)
MRI. If this issue needs to be overcome, QMUS will (also) have to measure more 
slices (i.e. at more locations) per muscle, for which new references values would 
have to be established at each specific location. Measuring the same muscle at 
different locations will (slightly) increase the time of a QMUS examination. But the 
current “single slice” QMUS measurements may still be a useful tool for follow-up 
studies. 
To conclude, both quantitative muscle ultrasound and quantitative muscle MRI 
are capable of detecting muscle pathology, and the results of both techniques 
correlate well. QMUS and QMRI are also complementary techniques. QMRI has 
the ability to investigate all muscles within one plain and to cover a larger area of 
interest compared to QMUS. MRI is therefore more applicable for pathologies with 
variations over the length of the muscles and involving deeper muscle layers. This 
makes MRI an excellent tool for diagnostic purposes. QMUS was found to have 
a larger dynamic range for following increasing muscle pathology and has the 
advantage that the exam can be performed at the bedside, is less costly, and can 
easily measure muscles from different limbs within a reasonable time. This makes it 
well suited for follow-up studies.
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Abstract
Objective:  To investigate the effects of aerobic exercise training (AET) and 
cognitive-behavioral therapy (CBT) on the progression of fatty infiltration and 
edema in skeletal muscles of patients with type-1 facioscapulohumeral muscular 
dystrophy using T2-MRI.
Methods:  Quantitative T2 MR images (qT2-MRI) and fat-suppressed T2-weighted 
images (Turbo Inversion Recovery Magnitude, TIRM) of the thigh were obtained 
on a 3T MR system  from 31 patients, of whom 13 received usual care (UC), 9 
AET, and 9 CBT. Muscle-specific fat-fractions (%) were derived from the qT2-MR 
images recorded at baseline and follow-up. Intervention effects were analyzed 
by comparing the fat-fraction progression rates between the UC and intervention 
groups with Mann-Whitney tests, while intermuscle differences were evaluated 
with a linear mixed model. Edematous lesions were identified on TIRM images.
Results: The intraclass correlation coefficient of the reproducibility of qT2-MRI 
fat-assessment was 0.99. Muscle fatty infiltration progressed on average 6.7% per 
year in the UC group.  Both interventions significantly lowered this rate to 2.9% 
per year in the AET group (AET – UC, p<0.05) and 1.7% per year in the CBT group 
(CBT – UC, p<0.01). The treatment effect differed among individual muscles. In 
both intervention groups fewer muscles developed edema than was observed in 
the UC group.
Interpretation: Fat-fractions and edematous lesions derived from (q)T2-MRI are 
reproducible and sensitive biomarkers to monitor intervention effects in individual 
muscles. These biomarkers report that muscular deterioration in FSHD type-1 is 
favorably affected by AET and CBT as reflected in decelerated fat replacement 
and reduced inflammation. 
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD), one of the most frequent 
myopathies1, is associated with progressive loss of strength, and with fatty 
infiltration and transient edema in skeletal muscles2. Muscle weakness and fatigue 
impose major limitations on the patients’ daily life3,4. Although the main genetic 
origins for the condition have been established and some potential molecular 
targets for treatment have been proposed, currently there is no cure for FSHD5,6. 
In a recent randomized clinical trial (RCT) we demonstrated that fatigue can be 
reduced and physical activity increased by aerobic exercise training (AET) and 
cognitive-behavioral therapy (CBT)7.  However, secondary outcome measures 
for physical capacity such as the six-minute walk test, aerobic capacity and 
muscle strength measurements8-10 did not show clear treatment effects7. This 
demonstrates the need for quantitative outcome measures that are more sensitive 
in detecting changes at the level of individual muscles.
It is well known that fat and edema in muscles can be detected by T2-MRI11-13. 
We presented fat-fraction determined with quantitative T2-MRI (qT2-MRI) as a 
non-invasive biomarker for affected muscles in patients with type-1 FSHD and 
showed that it highly correlates with clinical severity and muscle strength14. We 
recently also demonstrated that this biomarker can detect subclinical involvement 
of muscles, has prognostic value, and identifies changes due to natural disease 
progression in individual muscles over a period of four months15. Edematous 
muscle tissue presents as hyperintense areas on fat-suppressed T2-weighted 
images, and is indicative of inflammation16. It has been shown that in FSHD these 
bright signals precede fatty replacement of muscle tissue15,17. Thus, MRI-derived 
biomarkers seem very well suited to objectively monitor the results of existing and 
novel therapies for FSHD.
 
The primary goal of the present study was to examine, by qT2-MRI, if AET and 
CBT have an effect on the progression of fatty infiltration in individual leg muscles 
of type-1 FSHD patients. The muscular fat-fractions were correlated with the 
secondary outcome measures obtained from these patients7. In addition, we used 
fat-suppressed T2-weighted images to discover if the interventions change the 
presence of edema.   
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Patients and methods
Patients
We invited all the patients included in our multicenter RCT to assess the effects of 
AET and CBT on chronic fatigue in FSHD (the FACTS-2-FSHD trial)18 to take part 
in the present study. For all patients, the FSHD type-1 diagnosis was confirmed 
by DNA tests to identify the 4q35 deletion19. Inclusion and exclusion criteria were 
described previously18. Additional exclusion criteria were MR contraindications 
(i.e., claustrophobia, pacemaker). The informed consent form included a 
separate question enquiring whether the patients were willing to undergo an 
MRI investigation of the thigh muscles of one leg at the baseline and follow-up 
examinations.  
Study setup
The design of this study was published previously and the study was recorded 
in the Dutch Trial Register (NTR1447)18. Ethical approval was obtained from the 
institutional review board, and local approval received from each participating 
institution according to Dutch legislation. Each participant was randomly allocated 
to usual care (UC), AET, or CBT using a computer-generated randomization block 
list with random block sizes. 
Baseline demographics (age and gender) and FSHD severity data (10-grade 
clinical severity scale (CSS) 20) were collected. All clinical and MRI measurements 
were performed at the Radboud University Medical Center by two experienced 
physical therapists and two experienced MRI technicians, respectively, who 
remained blinded for treatment allocation throughout the study.  To achieve equal 
usual care periods for all three groups, the MRI exams were performed at baseline 
and after 12 weeks in the UC group, or at baseline and after intervention (16 
weeks) plus 12 weeks of UC in the AET and CBT groups 
Interventions
The interventions were delivered at nine healthcare centers across the 
Netherlands.  For a comprehensive description of the interventions we refer to 
our earlier trial by Voet et al.18 In short, participants in the AET group were asked 
to cycle three times a week for 30 minutes on an ergometer. During successive 
training sessions exercise intensity was gradually increased from 50 to 65% 
of heart-rate reserve. Cardiovascular load and compliance were continuously 
93
4
A
c
t
iv
e
 l
if
e
s
t
y
l
e
 d
e
c
e
l
e
r
a
t
e
s
 f
a
t
t
y
 in
f
il
t
r
a
t
io
n
 in
 F
S
H
D
monitored.  The CBT intervention aimed to reduce fatigue by optimizing the 
balance between actual behavior and physical capacity and included a structured 
patient-tailored activity program. The participants in the UC group received care 
as usual which in most patients was no treatment or occasional (conventional) 
physical therapy. 
Physical capacity measures
Participants were asked to wear an actometer around the ankle for 12 consecutive 
days21. Physical activity was averaged over the 12-day period and expressed as 
the average number of accelerations per 5-min intervals22,23. Aerobic exercise 
tolerance (VO2max in ml/min) was estimated using the Åstrand-Rhyming 
protocol24. In addition, the distance covered in a six-minute walk test (6MWT)25 
was recorded.
MRI
MRI exams were performed as reported previously15.  In short, upper-leg MR 
exams were performed on a 3 Tesla MRI system (TIM Trio, Siemens, Erlangen, 
Germany). A fish oil capsule served as a landmark for slice matching between 
the baseline and follow-up measurements. Scout images were acquired in three 
orthogonal directions to position the MRI slices of the subsequent scans. The 
protocol consisted of quantitative T2 multi-spin-echo imaging (qT2-MRI) and turbo 
inversion recovery magnitude (TIRM) imaging with an inversion time (TI) to null fat 
signals. The field of view (FOV) was set at 175x175 mm for all scans.  
To determine the reproducibility of our fat-fraction measurement procedure, the 
qT2-MRI exam was repeated in eight patients after a minimum of one hour and a 
maximum of one day after the first measurement.
MRI post-processing 
Analysis of the qT2-MR images was conducted offline with an IDL program (ITT 
Visual Information Solutions, Boulder, USA, v6.2) developed in-house. To compute 
separate fat and muscle images, the signal intensity of every smoothed pixel 
was fitted to a bi-exponential function with fixed relaxation times for fat (143 
ms) and muscle (40 ms). For each muscle, regions of interest (ROI) were carefully 
drawn on the corresponding T2-weighted MR image. ROIs were selected for the 
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rectus femoris (RF), vastus lateralis (VL), vastus intermedius (VI), vastus medialis 
(VM), sartorius (S), adductor longus (AL), adductor magnus (AM), gracilis (G), 
semimembranosus (SM), semitendinosus (ST), biceps femoris long head (BFL) and 
biceps femoris short head (BFS) (Figure 1). Subsequently, the mean fat-fraction (%) 
for every ROI was calculated by our IDL program. For a more extensive description 
of the quantification method see Kan et al14. To establish the reproducibility of the 
fat-fraction computation the same procedure was applied for the duplicate qT2-
MRI exams. 
 To ensure that edema would not interfere with the bi-exponential fitting, TIRM 
images were manually checked for high-intensity zones (MRI signature of edema); 
muscles images showing hyperintense areas were excluded from the qT2-MRI 
analysis. 
Statistics 
Pearson correlation analyses were performed between fat-fraction of the whole 
thigh musculature and the physical capacity measures using Prism 5.0 (GraphPad 
Software, San Diego, California, USA). For the test-retest reliability of the 
muscle-specific fat-fraction measurements by qT2-MRI, the intraclass correlation 
coefficient (ICC)26 was computed. 
Treatment effects were assessed in two ways. As they are not Gaussian distributed, 
the average changes in fat-fractions per year in the intervention groups were 
compared to those obtained for the UC group with one-tailed Mann-Whitney 
tests15. A linear mixed model for repeated measurements was used to assess 
effects on muscle-specific fat-fractions, with treatment (three levels: UC, AET, CBT) 
as the independent class variable and time (weeks since baseline measurement) 
and baseline fat-fraction as the independent continuous variable. In addition, 
interaction terms for treatment x baseline fat-fraction and treatment x time were 
included. Because we found no statistical significance for the interaction between 
treatment and baseline fat-fraction, the latter term was omitted from the model. 
In the UC group, regression per year was calculated using the data of the two 
measurement points. For the AET and CBT groups, the estimated difference 
in change per year, with 95% confidence intervals (CI) and corrected for pre-
treatment values, was compared to the UC group values. These analyses were 
performed by using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp, 
Armonk, New York, USA). Statistical significance was set at p<0.05. 
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Figure 1: Baseline (A) and 12-week follow-up (B) transversal T2-weighted MR images of the thigh of a 
34 year old male FSHD patient receiving usual care. Regions of interest (dashed lines) are drawn on the 
images of individual muscles to determine muscle-specific fat-fraction. AM = adductor magnus; BFL 
= biceps femoris long head; BFS = biceps femoris short head; G = gracillis; RF = rectus femoris; S = 
sartorius; SM = semimembranosus; ST = semitendinosus; VI = vastus intermedius; VL = vastus lateralis; 
VM = vastus medialis. Fatty infiltration is present in the BFL (30%), G (45%), ST (80%), SM (96%) and 
AM (16%). 
With qT2-MRI it was determined that the overall fat-fraction increased from 2% at baseline to 9% at 
follow-up, but that the progression rate depended on the muscle. In this illustrative case the fatty 
infiltration of the ST muscle increased to 91% at follow-up (fat-fraction increased with 11%). In contrast, 
no progression was observed in the VI, where the fat-fraction was stable at 2%.  
96
A
c
t
iv
e
 l
if
e
s
t
y
l
e
 d
e
c
e
l
e
r
a
t
e
s
 f
a
t
t
y
 in
f
il
t
r
a
t
io
n
 in
 F
S
H
D
4
Results
Subjects
Of the 57 patients participating in the FACTS-2-FSHD trial, 44 were willing to join 
the MRI study. The main reason for non-participation was claustrophobia. Twelve 
patients were not available for the follow-up MRI measurement (5 for personal 
reasons and 7 because of logistic problems). The data for one patient was 
discarded because of movement artifacts in the MR images. Hence, for 31 patients 
complete datasets were collected, with 13 patients having received UC, 9 AET and 
9 CBT. Demographics and clinical characteristics of the participants are presented 
in table 1. A Kruskal-Wallis one-way analysis of variance revealed no differences 
in age and clinical characteristics between the MRI-study participants and non-
participants.
The MRI data of 11 UC patients were derived from a study on the natural 
progression of fatty infiltration in FSHD15, and served as control data in the present 
evaluation.   
MRI
All NP/NA All UC AET CBT
Number of patients 
(male/female)
57
(37/20)
26
(15/11)
31
(22/9)
13
(10/3)
9
(7/4)
9
(8/3)
Age, years 52±14 50±14 53±14 53±15 56±15 53±12
CSS 2.8±1.0 2.8±1.1 2.8±1.0 3.0±0.9 3.1±1.1 2.3±1.0
Actometer 24h 39±16 36±16 42±15 43±16 40±16 43±14
6 minute walk test 423±148 416±133 428±167 455±169 386±147 456±190
Fat-fraction (%) NA NA 30±35 30±35 32±36 28±36
Table 1: Patient demographics and baseline characteristics
NP/NA: non-participant/not available for MRI study
UC: usual care
AET: aerobic exercise therapy
CBT: cognitive behavioral therapy
CSS:  clinical severity score
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Baseline MRI results
The fat-fractions of the leg muscles, as determined by qT2-MRI, ranged from 2 
to100 percent. Some patients presented without any abnormal fatty infiltration 
of the thigh muscles, whilst others showed severe fatty replacement of specific 
muscles (Figure 1). The baseline muscular fat-fractions of all patients (average 
value of all thigh muscles per patient) were negatively correlated with the baseline 
level of physical activity (R2=0.27, p=0.0013) as measured by the actometer, and 
with distance walked in the 6MWT (R2=0.40, p<0.0001), but were not significantly 
correlated with aerobic capacity (R2=0.09, p=0.053) (Figure 2).
Specific results of the measurements, such as type and number of fatty infiltrated 
muscles and muscles and fat fraction distribution over the length of muscles are 
described in a separate publication15.
To assess the test-retest performance of the fat-fraction determination, duplicate 
qT2-MRI measurements were performed. From the results of these measurements 
an intraclass correlation coefficient (ICC) of 0.99 was calculated.
To identify muscles with edema, associated with inflammation, we screened all 
thigh muscles for hyperintense signals on images obtained by the TIRM sequence. 
Eight muscles in the UC group, three in the AET group and eight in the CBT group 
were TIRM hyperintense at baseline. 
Figure 2: Correlations with common clinical capacity measures and measurement reproducibility 
of muscular fat-fraction in FSHD. Average fat-fraction of whole thigh musculature with A) physical 
activity and B) distance walked in the ‘6 minute walk test’ are negatively correlated with the average 
fat-fraction. C) There is no correlation between average fat-fraction of the thigh and the peak oxygen 
uptake.
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Therapy effects
In the UC group the fatty infiltration in the affected muscles progressed on 
average with 6.7% per year (Figure 3), with the linear mixed model analysis 
showing that progression occurred on average in all muscles except in the G, 
S and VL. The largest progression of fatty infiltration was found in the AM with 
19% per year (Table 2, Supplemental Figure 1). Six of the eight muscles of the 
UC group with hyperintense signal areas on the baseline TIRM images were also 
TIRM hyperintense at follow-up, while in this group seven muscles that had normal 
signal intensities at baseline had hyperintense lesions at follow-up. 
In the AET group the average change in fat-fraction per year was 2.9%, indicating 
that fatty infiltration progressed significantly slower than was observed in the 
UC group (p=0.03; Figure 3). The individual muscle analyses by a linear mixed 
model showed significantly less progression of fatty infiltration compared to the 
UC group in all but the G, S, SM and VL muscles (Table 2, Supplemental Figure 
1). The deceleration of fatty infiltration progression in the AET group was largest 
for the VM muscle. In this muscle no significant progression of fatty infiltration 
was observed whilst it was obvious in the UC group. In the AET group two out of 
three muscles with pretreatment TIRM hyperintensity were also hyperintense at 
follow-up (post intervention), and no muscles with new TIRM hyperintensities were 
observed. 
Figure 3: Treatment effects 
of aerobic exercise training 
(AET) and cognitive-behavioral  
therapy  (CBT) on MRI derived 
fat-fractions of the individual 
thigh muscles in FSHD type-
1 patients. Bars indicate the 
average change in fat-fraction 
per year for the thigh muscles 
of FSHD patients receiving no 
treatment (UC), AET or CBT. The 
progression of fatty infiltration 
was lower for the two treatment 
groups compared to UC. Values 
are presented as means±SE.
99
4
A
c
t
iv
e
 l
if
e
s
t
y
l
e
 d
e
c
e
l
e
r
a
t
e
s
 f
a
t
t
y
 in
f
il
t
r
a
t
io
n
 in
 F
S
H
D
Compared to the UC fat-fraction values, we also computed a significantly lower 
progression rate for the CBT group: on average 1.7% per year (p=0.0015, Figure 
3). The linear mixed model analyses showed that this deceleration applied to 
all muscles except for the G, S and VL (Table 2, Supplemental Figure 1). In this 
intervention group the effect was largest for the AM muscle. Of the eight muscles 
in the CBT group with TIRM hyperintensity at baseline five were still hyperintense 
after treatment, with two other muscles having become TIRM positive. 
100
A
c
t
iv
e
 l
if
e
s
t
y
l
e
 d
e
c
e
l
e
r
a
t
e
s
 f
a
t
t
y
 in
f
il
t
r
a
t
io
n
 in
 F
S
H
D
4
O
bs
er
ve
d 
fa
t- 
fra
ct
io
n 
(%
) 
Es
tim
at
ed
 m
ea
n 
ch
an
ge
 in
 fa
t-f
ra
ct
io
n 
(%
 p
er
 y
ea
r)
M
us
cle
fo
r a
ll g
ro
up
s 
at
 b
as
el
in
e 
pe
r y
ea
r i
n 
UC
AE
T 
- U
C 
 
ad
ju
st
ed
 fo
r b
as
el
in
e 
va
lu
es
C
B
T 
- U
C
 
ad
ju
st
ed
 fo
r b
as
el
in
e 
va
lu
es
M
ea
n 
(S
D
)
M
ea
n 
(9
5%
 C
I)
M
ea
n 
(9
5%
 C
I)
p
M
ea
n 
(9
5%
 C
I)
 p
AM
38
.1
1
(3
9.
16
)
 
18
.9
5
(1
1.
84
 to
 2
6.
06
)
 
-1
4.
34
(-2
3.
84
 to
 -4
.8
4)
0.
00
 
-2
0.
54
(-3
0.
61
 to
 -1
0.
47
)
0.
00
B
FL
35
.2
1
(3
8.
03
)
12
.7
4
(7
.5
2 
to
 1
7.
95
)
-1
3.
28
(-2
0.
32
 to
 -6
.2
4)
0.
00
-1
3.
76
(-2
1.
23
 to
 -6
.2
8)
0.
00
B
FS
33
.0
7
(3
5.
70
)
9.
09
(4
.1
3 
to
 1
4.
05
)
-5
.7
5
(-1
2.
31
 to
 0
.8
1)
0.
08
-1
0.
49
(-1
7.
56
 to
 -3
.3
4)
0.
01
G
27
.6
6
(3
7.
54
)
1.
74
(-3
.1
6 
to
 6
.6
4)
-2
.2
7
(-8
.7
0 
to
 4
.1
6)
0.
48
1.
40
(-5
.5
9 
to
 8
.4
0)
0.
69
RF
36
.2
3
(3
7.
22
)
9.
25
(2
.8
6 
to
 1
5.
64
)
-7
.9
6
(-1
6.
31
 to
 0
.3
8)
0.
06
-1
0.
28
(-1
9.
48
 to
 -1
.0
9)
0.
03
S
19
.7
7
(2
6.
03
)
2.
19
(-2
.6
6 
to
 7
.0
3)
-1
.3
1
(-7
.6
9 
to
 5
.0
6)
0.
68
1.
54
(-5
.5
0 
to
 8
.5
8)
0.
66
SM
54
.4
7
(4
0.
22
)
11
.3
3
(4
.5
2 
to
 1
8.
13
)
-6
.0
8
(-1
5.
07
 to
 2
.9
2)
0.
18
-1
5.
86
(-2
5.
64
 to
 -6
.0
9)
0.
00
ST
41
.7
5
(4
1.
56
)
10
.9
5
(6
.3
9 
to
 1
5.
50
)
-9
.6
2
(-1
5.
64
 to
 -3
.5
9)
0.
00
-8
.5
8
(-1
5.
32
 to
 -1
.8
5)
0.
01
VI
14
.6
8
(2
2.
78
)
9.
26
(5
.6
4 
to
 1
2.
87
)
-8
.2
1
(-1
2.
92
 to
 -3
.5
9)
0.
00
-1
1.
30
(-1
6.
69
 to
 -5
.9
1)
0.
00
VL
13
.2
5
(2
3.
30
)
1.
91
(-0
.6
1 
to
 4
.4
3)
-1
.2
3
(-4
.5
2 
to
 2
.0
6)
0.
45
-3
.6
8
(-7
.5
6 
to
 0
.2
0)
0.
06
VM
19
.3
2
(2
8.
88
)
 
15
.9
2
(1
1.
80
 to
 2
0.
04
)
 
-1
6.
18
(-2
1.
58
 to
 -1
0.
78
)  
  
0.
00
 
-1
7.
46
(-2
3.
60
 to
 -1
1.
31
)
0.
00
Ta
bl
e 
2:
 R
es
ul
ts
 o
f i
nt
er
ve
nt
io
n 
ef
fe
ct
s 
on
 p
ro
gr
es
sio
n 
of
 fa
tty
 in
fil
tra
tio
n 
pe
r w
ee
k 
fo
r t
he
 in
di
vi
du
al
 m
us
cl
es
, u
sin
g 
a 
lin
ea
r m
ix
ed
 m
od
el
 fo
r r
ep
ea
te
d 
m
ea
su
re
m
en
ts
A
 li
ne
ar
 m
ix
ed
 m
od
el
 w
as
 u
se
d 
to
 a
cc
ou
nt
 fo
r r
ep
ea
te
d 
m
ea
su
re
m
en
ts
. 
Ba
se
lin
e 
fa
t-f
ra
ct
io
ns
 (%
) a
s 
m
ea
n 
va
lu
es
 (S
D
) a
nd
 e
st
im
at
ed
 c
ha
ng
e 
pe
r y
ea
r i
n 
fa
t-f
ra
ct
io
ns
 a
s 
m
ea
n 
va
lu
es
 (9
5%
 C
I).
 U
C
: u
su
al
 c
ar
e,
 A
ET
: a
er
ob
ic
 e
xe
rc
ise
 
tra
in
in
g,
 C
BT
: c
og
ni
tiv
e-
be
ha
vi
or
al
 th
er
ap
y. 
 A
M
 =
 a
dd
uc
to
r m
ag
nu
s;
 B
FL
 =
 b
ic
ep
s 
fe
m
or
is 
lo
ng
 h
ea
d;
 B
FS
 =
 b
ic
ep
s 
fe
m
or
is 
sh
or
t h
ea
d;
 G
 =
 g
ra
ci
lli
s;
 R
F 
= 
re
ct
us
 fe
m
or
is;
 S
 =
 S
ar
to
riu
s;
 S
M
 =
 s
em
im
em
br
an
os
us
; S
T 
= 
se
m
ite
nd
in
os
us
; V
I =
 v
as
tu
s 
in
te
rm
ed
iu
s;
 V
L 
= 
va
st
us
 la
te
ra
lis
; V
M
 =
 v
as
tu
s 
m
ed
ia
lis
.
101
4
A
c
t
iv
e
 l
if
e
s
t
y
l
e
 d
e
c
e
l
e
r
a
t
e
s
 f
a
t
t
y
 in
f
il
t
r
a
t
io
n
 in
 F
S
H
D
Discussion
The main finding of this study is that aerobic exercise therapy (AET) and cognitive-
behavioral therapy (CBT) slow down the progression of fatty replacement of 
muscle tissue in FSHD type-1 as evidenced by quantitative T2-MR imaging, 
making this the first study to demonstrate that MRI-derived fat-fraction can serve 
as a sensitive and reproducible biomarker to reveal treatment effects in FSHD. 
This is clinically relevant as we also demonstrate that fat-fractions correlate with 
physical activity and distances walked in 6 minutes. Moreover, compared to the 
results obtained in FSHD patients receiving usual care, in the patients having 
completed AET or CBT fewer muscles showed TIRM hyperintensity, the MRI 
signature for edema, thus indicating a reduced inflammatory response. 
Previously, we proved that the qT2-MRI-derived muscular fat-fraction is a sensitive 
biomarker of disease state in FSHD and that it can detect natural progression in 
individual muscles within the course of four months15, whilst leg muscle strength 
and MR-detected muscle fat infiltration were shown to correlate14,15,27. Recently, 
Arpan et al demonstrated that T2-MRI also allows identifying therapeutic effects 
(of corticosteroids) in muscles of boys with Duchenne muscular dystrophy28. With 
the current qT2-MRI study we were able to substantiate that both AET and CBT 
interventions significantly decelerate disease progression in thigh muscles within 
a time span of four months, while our muscle-specific linear mixed model analyses 
showed that treatment effects were not the same for all muscles. For instance, 
improvements were most pronounced in the adductor magnus and vastus medialis 
but absent in the gastrocnemius, sartorius and vastus lateralis muscles. The latter 
observation can easily be explained by the non-significant fatty progression rates 
for these muscles in the usual care group across the trial period.
In the absence of a causal treatment for FSHD it is important to find 
approaches that can slow down disease progression29. Of the studies exploring 
pharmacological and non-pharmacological interventions9,10,29-34, only some physical 
therapy programs showed a beneficial effect, while their application remains 
controversial due to the lack of controlled studies29. In our recently published 
randomized controlled trial, we reported that both AET and CBT significantly 
reduced chronic fatigue in FSHD patients as assessed with the Checklist Individual 
Strength (CIS-fatigue) scale18, whereas objective physical outcome measures, did 
not improve, suggesting that the decrease in perceived fatigue levels was not 
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mediated by increased physical fitness or improved functioning. Similar physical 
capacity measures also failed to detect significant effects in other FSHD treatment 
trials31,35,36. Using the fat-fractions derived from qT2-MR imaging, we were able to 
demonstrate significant treatment effects, from which we infer that determining 
fatty infiltration volumes in skeletal muscles is a more sensitive instrument than 
mentioned physical capacity measures, even though we found these measures to 
correlate with fatty infiltration averaged over all thigh muscles.
 
Several factors may explain the lack of sensitivity of physical capacity measures. 
For instance, muscle force assessments can be influenced by limb and body 
position, pain, and fear of overuse, while functional measures are sensitive to 
fatigue, encouragement, and motivation and may be influenced by learning and 
placebo effects 36. Moreover, these measures gauge the physical performance of 
the patient as a whole or an entire muscle group and, consequently may obscure 
the detection of improvements in individual muscles. Finally, physical function 
measures are less reproducible than fat-fractions obtained by qT2-MRI37. 
Various aspects need to be taken into account when interpreting the results. We 
derived positive treatment effects from two consecutive MRI exams in a total of 
31 patients, while 57 patients were included in the original RCT. However, as we 
found no significant differences between the 31 participants and the 26 non-
participants, we do not expect that selection bias played a relevant role. To correct 
for control and intervention group differences in timing between the baseline and 
follow-up measurement we normalized the change in fat-fractions for all groups 
to one year. This assumes linear progression of fatty infiltration, which might not 
reflect its true course. Because the time between the two measurements was 
longer in the intervention groups than in the usual care group, a relatively strong 
disease progression was to be expected in these intervention groups, with the 
necessary normalization step possibly obscuring treatment effects. We hence 
conclude that the deceleration of fatty infiltration as observed in the intervention 
groups cannot have been positively biased by the applied normalization 
procedure. 
Exercise enhances several capacities that will lead to stronger muscles and less 
fatigue, but may also provide favorable conditions to slow down progression 
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of muscle affliction and possibly to regenerate muscles in neuromuscular 
diseases38,39. A primary role in the pathophysiology of FSHD has been suggested 
for a DUX4 induced immune response2. This is in agreement with the observation 
of hyperintense signals in TIRM or STIR MR images of muscles in patients, which 
are indicative of edematous inflammation14,16,40. The MR signatures for edema 
and/or inflammation are of particular interest as they seem to precede the fatty 
infiltration process15,17. Moreover, biopsies of FSHD muscles have shown increased 
pro- and anti-inflammatory cytokines40 while exercise is known to have anti-
inflammatory effects41. 
In conclusion, with qT2-MRI we were able to show a significant deceleration in the 
rate of fatty infiltration in individual muscles of patients with type-1 FSHD after 
AET and CBT compared to usual care. Future clinical trials in patients with muscle 
disease may then include MRI as a direct, sensitive and objective measure of 
muscle tissue state.
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Appendix
 Reproducibility qT2-MRI
Introduction
Muscular fat-fraction determined by 
quantitative T2-MRI (qT2-MRI) has 
proven to be a valuable biomarker in 
the clinical assessment of patients with 
facioscapulohumeral muscular dystrophy 
(FSHD)14. Moreover, recently we showed 
that this biomarker can detect pre-clinical 
involvement, has prognostic value, and 
allows to follow natural progression of 
muscle deterioration over a four-month 
period15. Therefore, this biomarker 
seems very well suited for follow-up 
studies and to objectively evaluate FSHD 
therapies. When fat-fraction determined 
by qT2-MRI will be chosen as a primary 
outcome it requires accurate knowledge 
of the reproducibility of this measure to 
determine the number of participants that 
need to be included in a trial in order to 
establish an effect (power estimation). 
We aimed to calculate the reproducibility  
of qT2-MRI determined muscular fat-
fraction in patients with the common 
muscular dystrophy FSHD as well as in healthy volunteers. 
Figure 1: A) Quantitative fat-fraction map of a 
FSHD patient with severe fatty infiltration in the 
hamstring muscles. Muscular fat-fraction ranges 
from 0 to 100%. B) Corresponding T2-weighted 
MR image. Regions of interest were carefully 
drawn on every individual muscle. 
106
A
c
t
iv
e
 l
if
e
s
t
y
l
e
 d
e
c
e
l
e
r
a
t
e
s
 f
a
t
t
y
 in
f
il
t
r
a
t
io
n
 in
 F
S
H
D
4
Methods 
Recruitment: Eight genetically proven FSHD type-1 patients (4 male, 4 female, 
mean age: 55±11 years, clinical severity score 20: 2.4±0.9) and four healthy young 
volunteers (2 male, 2 female, mean age 22±1 years) were included. 
MR protocol: MR was performed on a 3T Siemens Trio using a 1H volume coil 
around one upper leg of the subject. The qT2-MRI measurement was performed 
in duplicate after at least one hour and at maximum one day after the first 
measurement. A marker was positioned at 1/3 of the distance between the spina 
iliaca anterior superior and patella, to allow for accurate slice matching between 
the two measurements. Multi spin-echo MR images were recorded of the same 
location (TR: 3 sec, TE: 16 echo times 7.7 ms - 123.2 ms, 4-8 slices; limited by SAR, 
slice thickness/gap 6 mm/9 mm, FOV 175 mm x 175 mm).
Analysis: Fat content was derived from multi spin-echo images by fitting the 
signal intensity to a bi-exponential function with fixed T2 relaxation times for 
muscle (40 ms) and fat (143 ms)14. This was done with a custom-made IDL program 
calculating muscle and fat-fractions, producing fat-fraction maps of the image (Fig. 
1A) Muscle fraction = 1- fat-fraction. Regions of interest were carefully drawn for 
every individual muscle to yield a muscle specific fat-fraction (Fig. 1B). 
Reproducibility assessment: The reproducibility was assessed by a Bland-Altman 
analysis. These analyses were performed using Prism 5.0 (GraphPad Software, San 
Diego, California, USA).
Results 
Duplicate qT2-MRI measurements of skeletal muscle were performed and the fat-
fraction analysis was performed in duplicate for every single muscle. This resulted 
in duplicate values for 80 FSHD muscles and 45 muscles of healthy subjects. 
The fat-fractions from both measurements were subjected to a Bland-Altman 
analysis. For the FSHD muscle this revealed a coefficient of repeatability for the 
determination of muscle specific fat-fraction of 6.5 % (1.96 * SD). The 95 % limits 
of agreement were -5.2 % and 7.8 % (Fig. 2). The reproducibility of the fat-fraction 
assessment was independent of the fat-fraction.
The reproducibility was found to be much higher for the healthy volunteers, with a 
coefficient of repeatability of 2.8% and 95% limits of agreement for -2.5% to 3.2% 
(Fig. 2).
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Discussion 
Our analysis shows that muscle specific fat-fraction can be reliably determined 
with a coefficient of repeatability of 6.5% in FSHD muscle, and is independent of 
fat-fraction. In healthy subjects higher coefficients of repeatability are found 14,42,43, 
in agreement with our findings of a coefficient of repeatability as low as 2.8%. 
However, this cannot be taken as representative for patients because the range 
of fat-fraction observed in healthy volunteers is very limited (0 – 8%) compared 
to the range of fat-fractions found in patients (0 - 100%). The difference between 
the patients and the healthy volunteers may be explained by the difference in age 
between the two cohorts. 
For accurate power estimations for future trials knowledge on the reproducibility 
or measurement error is crucial. With a coefficient of repeatability of 6.5% a 
treatment effect of 8% would be determinable when 9 data-points are included 
in each group. Meaning 9 patients per group for a muscle specific analysis. For 
a general analysis 9 patients would yield data from at least 90 muscles. With this 
coefficient of repeatability this would mean that treatment effects of around 2.5% 
would be picked up by statistical analyses of that data. For instance, this validates 
the group sizes in this and the previous chapter.
Figure 2: Bland- Altman analysis of the MRI determined muscle specific fat-fraction. The dot-dashed 
line indicates the mean difference and the dashed lines indicate the limits of agreement (95% CI). The 
reproducibility of the method is high for healthy volunteers compared to patients with FSHD. This is 
likely due to the limited range of fat-fraction found in healthy subjects, in contrast to the entire range 
(0 – 100%) in patients with a FSHD.
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Abstract
Background: Creatine (Cr) is recognized as an effective nutritional supplement, 
however there is a wide variation in the responsiveness between individuals, which 
urges for a non-invasive assessment of the fate of Cr in individual muscles. The aim 
of this study was to introduce 3D 13C MRSI of the leg to monitor simultaneously 
13C Cr and phosphocreatine (PCr) in individual muscles during and after the 
ingestion of 13C-4 labeled Cr, to assess its uptake, turnover and PCr over total Cr 
(TCr) ratios for different muscles. 
Methods: 13C MRSI experiments were performed in seven subjects (two males and 
two females (all ~20 years old), one 82-year old male, and two FSHD patients) of 
the posterior thigh at 3T with a 1H/13C MR (half-)volume coil before, during and 
after the ingestion of 13C-4 labeled Cr. This allowed simultaneously investigation of 
5 different hamstring muscles. Subjects ingested 20 g Cr per day for four days in 
four 5 g doses (15% 13C enriched) at equally spaced intervals throughout the day. 
Results: A one-way ANOVA didn’t reveal a statistical significant muscle specific 
uptake rate for the young healthy subjects, but the males in the study had a 
significantly higher uptake rate compared to females (p=0.01). Cr turnover (about 
2% per day) could only be determined in muscles if Cr uptake was observed. 
Average PCr/TCr ratios were about 0.7 in all subjects and all investigated 
muscles, except that the PCr/TCr ratio of the adductor magnus muscle was 
significantly lower (0.64±0.03) compared to that of the semi tendinosus (p<0.01), 
membranosus (p=0.03) and biceps femoris (p=0.03). 
Conclusions: Dynamic 13C MRSI in combination with 13C Cr supplementation 
makes it possible to study Cr uptake, turnover and PCr/TCr ratios in vivo for 
individual muscles in one exam. Our results suggest a gender specific effect of Cr 
uptake.    
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Introduction
Creatine (Cr) is a naturally occurring compound in fish and meat and is 
endogenously produced in the liver and kidneys1. Cr is taken up from blood 
vessels into tissues with high energy requirements such as muscle and brain2. 
This uptake is facilitated by a specific creatine transporter protein (CrT), which 
transports the compound together with sodium into the cell against a creatine 
concentration gradient3. Inside the cell Cr becomes a substrate in the creatine 
kinase (CK) reaction in which it is reversibly phosphorylated to phosphocreatine 
(PCr). This Cr-PCr system has an important role in energy metabolism as a 
temporal energy buffer and by ‘facilitating substrate diffusion’ in spatial energy 
distribution4. A spontaneous reaction irreversibly degrades both Cr and PCr into 
creatinine, which is excreted via the kidneys5,6. Because PCr stores are depleted 
in some dystrophic muscles7 and because of potential cellular protective effects8, 
Cr supplementation has been proposed as treatment for several neuromuscular 
disorders9.
Even though Cr is recognized as an effective nutritional supplement for athletes 
and to improve symptoms in several muscle, bone and brain diseases9-11, 
there is a wide variation in the responsiveness to Cr supplementation between 
individuals12,13. This may be due to various factors determining Cr uptake such 
as intracellular Cr concentration and fiber type composition14,15. The different 
contributions of these factors can be muscle specific in healthy individuals and 
will change with age16 or due to a disease in muscles17. Therefore a direct in 
vivo method is needed to monitor creatine uptake and metabolism in individual 
muscles.
Magnetic resonance spectroscopy (MRS) has the unique capability that it can 
measure the presence of Cr and PCr in tissues non-invasively in humans. With 
proton (1H) MRS it is possible to observe only the total amount of Cr (TCr) in 
muscles as the individual signals of free Cr and PCr are overlapping in spectra 
obtained in vivo and with phosphorus (31P) MRS it is possible to monitor PCr18. 
Both 1H and 31P MRS have been used to study TCr and PCr increases in skeletal 
muscle after Cr supplementation19-22. To examine these two compounds 
simultaneously in the same exam is complicated as different RF and hardware 
components are required for each nucleus and a quantitative assessment by 
sequential measurements is hampered by the required calibrations23. By carbon 
(13C) MRS it is possible to observe separated signals for Cr and PCr simultaneously 
in spectra of skeletal muscles, but because of the low natural abundance of 13C in 
the body this is not a very sensitive method. However, with the oral ingestion of 
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13C-4 labeled Cr the signal-to-noise ratio can be increased and we demonstrated 
that in this way also the uptake and turnover rates of supplemented Cr can be 
assessed instead of the increase of the TCr pool24.  In this study only a single 
subject was included and no particular localization to a specific muscle was 
applied apart from the use of a surface coil adjacent to the calf. Spatially resolved 
MR spectra can be acquired with MR spectroscopic imaging (MRSI) and therefore 
allows for muscle specific detection of metabolites25, but 13C MRSI has been rarely 
applied in human studies.  
The aim of the study described in the present paper was to investigate the 
performance of 3-dimensional 13C MRSI of the posterior thigh at 3T with a 1H/13C 
MR (half-)volume coil before, during and after the ingestion of 13C-4 labeled Cr, 
to assess its uptake, turnover and PCr/TCr ratios for different muscles in a single 
examination. For this purpose we examined seven volunteers, including two 
patients with the neuromuscular disease facioscapulohumeral muscular dystrophy 
(FSHD). In addition we determined T1 relaxation times of the 13C-C4 spins of 
creatine in healthy muscles. 
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Materials and methods
Subjects
For this feasibility study we included four healthy young volunteers (YH), one 
82-year-old male (OH), and two genetically confirmed FSHD patients. We made 
sure none of the participants had an MR contraindication (pacemaker, metal 
implants or claustrophobia) before being included in this study. None of the 
subjects performed sports at a professional level, were vegetarian, or were taking 
Cr as supplementation.  
Participants’ demographics are listed in table 1. Ethical approval was obtained 
through the institutional review board, and written informed consent was obtained 
from all participants.
Age (years) BMI (kg/m2) Weight (kg) Gender
Young Healthy #1 23 20.94 57 Female
Young Healthy #2 21 20.62 58 Male
Young Healthy #3 21 22.06 63 Female
Young Healthy #4 21 21.90 85 Male
Old Healthy 82 30.67 95 Male
FSHD #1 72 33.46 90 Female
FSHD #2 41 24.68 73 Male
Table 1: Participants demographics
Study design
Participants ingested 20 g Cr per day for four days in four 5 g doses (15% 13C 
enriched at the guanidino carbon, 13C-4-Cr) at equally spaced intervals through 
the day. They were instructed to dilute the Cr in a glass of lukewarm water and to 
drink it along with 250 ml of standard carbohydrate solution to augment skeletal 
muscle Cr accumulation26.  On the day of the first measurement the participant 
was given the 16 portions of the 13C enriched Cr, and was instructed to start the Cr 
supplementation the next day. 
The full study design consisted of 12 MR measurements at day 0, 1, 2, 3, 4, 
5, 7, 12±1, 14±1, 19±2, 41±3, 78±3 and 105±3. Day 0 was the baseline 
measurement, days 1 – 4 were during Cr supplementation, and the remaining 
measurements were after Cr supplementation. The measurement protocol was 
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reduced to 6 MR measurements for the additional subjects; one measurement 
before Cr supplementation (day 0), 2 during (days 2 and 5), and three after (days 
19, 41 and 78) Cr supplementation. 
Blood and urine samples were taken on days 0, 3 and 7 to monitor kidney 
function during Cr supplementation. Venous blood was drawn directly into a K2-
EDTA vacuum tube. Tubes were centrifuged at 3000 revolutions per minute for 
10 minutes, subsequently the plasma was separated from the packed red blood 
cells and was stored at -80oC until analysis. Cr and 13C-4-Cr concentrations were 
determined with mass spectroscopy. 
MR protocol
MR exams were performed on a clinical 3 Tesla MRI system (Tim Trio, Siemens, 
Erlangen, Germany) with a 1H birdcage volume coil and a circularly polarized 13C 
half-volume coil inserted into the 1H coil. A fish oil capsule served as a matching 
landmark between the MR exams and was positioned at one-third the distance 
between the spina iliace anterior superior and the patella. Subjects were placed 
feet first supine inside the magnet bore, the coil was placed around the right 
upper leg. After scout imaging the protocol consisted of T2 multi spin-echo 
imaging (qT2-MRI) (field of view 175mm x175mm, repetition time (TR) 3000 ms, 
16 equally spaces echo times (TE) 7.7-123.2 ms, 8 slices, slice thickness/gap 
6mm/9mm). 
Followed by a 13C 3D MRSI with an adiabatic BIR45 excitation pulse centered 
at 157 ppm, which is between the resonance frequencies of Cr and PCr, (FOV 
200x200x400mm, TR 1000ms, matrix size 10x10x8, Hamming weighted k-space 
acquisition, bandwidth 10kHz, vector size 1024, 30 averages with WALTZ16 proton 
decoupling during acquisition). 
In one subject a T1 measurement was performed at day 10, by acquiring 13C 
free induction decays (with adiabatic excitation and 150 averages) at different 
repetition times (TR= 0.75, 1, 2, 3, and 8 seconds).
Because of the 13C coil profile only spectra from the posterior thigh muscles, more 
specifically the biceps femoris (BF), semimembranosus (SM), semitendinosus (ST), 
adductor magnus (AM) and the gracillis (G) were collected (Fig. 1). The entire MR 
examination took about one hour, including subject placement. All MRSI datasets 
were saved as raw files for off line processing.
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Data analyses
Muscle specific fat-fractions were determined by fitting the signal of the multi-spin 
echo images to a bi-exponential function with fixed relaxation times for fat and 
water as described previously27. A spatial 100% Hamming filter was applied to 
the 13C MRSI k-space data before voxel selection. From every slice in the field of 
view of the 13C coil one voxel was selected per muscle. Voxels were selected with 
the program 3DiCSI28. Only voxels were selected reliable lying within one muscle, 
resulting in three voxels per muscle on average. The corresponding free induction 
decays (FID) were exported to jMRUI 4.0 for spectral fitting29.
Spectral fitting
Voxels from the same muscle were summed, subsequently unwanted lipid 
resonances were removed from the 13C spectra with an HLSVD filter30,  and 
the spectra were apodized by 10Hz. Assuming a line width ratio of 0.81 and a 
frequency difference of 30 Hz  between Cr (157.5 ppm) and PCr (156.6 ppm) 
the signals were fitted with AMARES to Gaussian line shapes31. Since the Cr and 
PCr pools are in equilibrium32, summed signal intensities of Cr and PCr served as 
TCr. Spectral quality was assessed by comparing the TCr signal intensity to the 
standard deviation (SD) of the noise (defined as SD of the last 10% of the FID). 
Only spectra in which the TCr signal intensity was larger than the SD of the noise 
were included for further analysis. 
Creatine uptake
TCr amplitudes of days 0 till 5 were fitted to a linear function (equation 1) where 
TCr(t) is the 13C signal intensity at measurement day t. The fitted slope gives the Cr 
uptake rate (kup) and the intercept the initial TCr value (TCr0), both in arbitrary units 
(a.u.). The final uptake rate is presented as kup/TCr0 to give a value expressed in 
percentage per day. The error of the fit was treated as the standard deviation. 
         eq. 1
Creatine turnover
TCr signal intensities from day 5-105 were used to calculate the turnover rate. 
Cr breakdown is assumed to follow first order kinetics33 so TCr signal intensities 
were fitted to a mono-exponential function (equation 2), under the assumptions 
described in Kan et al., 200624. The maximal 13C TCr signal intensity is TCrmax, 
and kbr is the breakdown rate (% per day). The error of the fit was treated as the 
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standard deviation. All curve fitting was done using Prism 5.0 (GraphPad Software, 
San Diego, California, USA). 
         
eq. 2
PCr/TCr ratio
The PCr/TCr ratio was determined per muscle over time for every measurement 
point unless the Cr and PCr signals could not be resolved properly. To compare 
the PCr/TCr ratios between individual muscles the PCr/TCr ratios were averaged 
over all these measurement points. 
T1 measurement 
The Cr and PCr signal intensities were fitted as a function of the repetition time 
according to equation 3, giving a value for the T1 relaxation time in ms.
         
eq. 3
Statistics
Blood plasma concentrations were compared to day 0 with a one-sided paired 
t-test. Muscle specific effects of Cr uptake and PCr/TCr ratios were assessed by 
one-way ANOVAs. All statistical analysis were done using Prism 5.0 (GraphPad 
Software, San Diego, California, USA), and statistical significance was set at 
p<0.05.
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Results
General observations
None of the subjects reported side effects of the creatine supplementation. Blood 
analysis of the creatine content and 13C enrichment indicated that all subjects 
adhered to the prescribed intake of the supplementation (Table 2). There was 
no significant difference in creatine and enrichment values between males and 
females at day 3. Two days after the supplementation period the creatine levels 
had returned to normal values, but the 13C enrichment was still increased. In the 
13C MR spectra of the posterior thigh muscles separate signals for PCr and Cr were 
seen (Figs. 1 and 2). After ingestion of 20 g/day 15% labeled 13C-4-Cr a variable 
increase of the PCr and Cr signal intensities was observed in these muscles (Fig. 2). 
Lowest Cr uptake rate was observed in the adductor magnus muscle and largest in 
the semi membranosus muscle (Fig. 3).  Cr turnover rates and in particular PCr/TCr 
ratios were less variable between muscles and subjects (Fig. 6).
Figure 1: 13C MRSI grid with voxels overlaid on T2-weighted image of the right thigh of a healthy young 
male after four days of creatine supplementation. The 13C half-volume coil is positioned adjacent to the 
hamstring muscles. The spectra are zoomed on the creatine signals. Only the hamstrings muscles are in 
the field of view of the coil including the biceps femoris (BF), semi tendinosis (ST), semi membranosus 
(SM), gracillis (G) and adductor magnus (AM), as delineated in the image.
122
c
r
e
a
t
in
e
 u
p
t
a
k
e
 a
n
d
 t
u
r
n
o
v
e
r
 a
s
s
e
s
s
e
d
 b
y
 13C
 M
R
S
I
5
Figure 2: 13C MR spectra before, during and after creatine supplementation in the AM muscle of a 
healthy young male subject. A) Complete 13C MR spectrum of the AM muscles at day 7, three days 
after the creatine supplementation period. Cr and PCr resonate at 157.5 and 156.6 ppm respectively. 
Even though the creatine is enriched the signal intensity is still much smaller compared to the lipid 
resonances, which is the natural abundance signal. B) A clear increase in signal intensity is observed 
during the 13C-4-Creatine supplementation period follow by a slower decrease; the signal is still 
elevated up to day 108.

 





 
           

 




Day 0 Day 3 Day 7
Plasma Creatine (µM) 38 ± 23 668 ± 432** 41 ± 6
%13C 6.0 ± 0.6 19 ± 6.1** 10 ± 0.5**
Table 2: Plasma Creatine and 13C-4-Creatine concentrations (mean±std), day 3 and day 7 values are 
compared to day 0 by means of a one-sided paired t-test.
** p<0.01
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Creatine uptake
The TCr signal increase from day 0 till day 5 was fitted to a linear function to yield 
a subject and muscle specific uptake rate. This analysis could be performed in 18 
of the 20 investigated muscles. In subject #1 the spectral quality of the BF muscle 
was not sufficient to reliably fit the creatine signals and in subject #3 the G muscle 
was too thin to place a voxel solely in that muscle In subject #1 the ST muscle 
showed a clear Cr uptake, while a low uptake was observed in the G muscle. 
Even though the signal to noise of the spectra was sufficient to identify and fit 
the Cr and PCr signals, no creatine uptake was observed in the other muscles 
of this subject. In both subject #2 and #4 significant Cr uptake was observed in 
SM and ST muscles. Only little Cr uptake was observed in 4 muscles of subject 
#3. Although creatine uptake was variable between different muscles a one-
way ANOVA did not reveal a statistical significant difference between averages 
of the different muscles  (p=0.08) (Fig. 3). Taking all muscles together there is a 
significant higher uptake rate in the male muscles compared to the female muscles 
(p=0.04 one-sided t-test), this effect was most clear for the SM muscle (p=0.01).
Figure 3: Muscle specific creatine uptake rates (% per day) in young healthy volunteers (n=4). Subjects 
1 and 3 were female and 2 and 4 male. For each subject the uptake rates are presented from left to 
right: semi-tenidinosus (ST), semi-membranosus (SM) adductor magnus (AM) biceps femoris (BF) and 
gracillis (G) Although the Cr uptake rates vary over the muscles a one-way ANOVA did not reveal a 
statistical significant difference between the average values of specific muscles. Bars indicate the mean 
uptake rate per muscle and the error bars indicate the standard deviation. 
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Creatine turnover
The Cr turnover was determined by fitting the TCr signal intensities from day 
5-105 (after supplementation) to a mono-exponential decay function. Because all 
turnover curves could be fitted to this function, even when no Cr uptake had taken 
place, we added a fit quality criterion that R2 has to be larger than 0.5 to ensure 
that the fitted values indeed follow a mono-exponential decay. This was only true 
for three muscles of subject #2 and two muscles in subject #4, both male subjects. 
No reliable turnover rates could be determined for both female volunteers. 
Over the muscles in which the Cr turnover could be determined the rates were 
comparable with an average of 2.1±0.7% per day (Fig. 4). 
Figure 4: Muscle specific Cr turnover rates (% per day) in young healthy volunteers (n=4). Only muscles 
in which the turnover signals were found to follow a mono-exponential decay were included. Turnover 
rate could not be determined if muscles showed low Cr uptake. Bars indicate the mean uptake rate, 
error bars indicate the standard error and the circles are the individual values.
T1 relaxation times of  13C-4 spins  
In one healthy young male subject the T1 relaxation times of the hamstrings were 
measured by analyzing the 13C-4 signals of Cr and PCr in relation to the repetition 
time.  The T1 of Cr was found to be 341±36 ms and for PCr 413±49 ms. 
PCr/TCr ratio
To investigate if creatine supplementation would change the PCr/TCr ratio we 
determined this ratio for every time point during and after the supplementation. 
For none of the examined muscles we observed a change in the PCr/TCr ratio 
during this period; an example of values for this ratio are shown for the ST muscle 
in figure 5.
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Per muscle we determined PCr/TCr ratios averaged over all time points (Table 
3). Corrections for differences in T1 did not affect the ratios. A one-way ANOVA 
didn’t show a muscle specific effect for the PCr/TCr ratio (p=0.32) (Fig. 6, Table 
3), however the muscle specific PCr/TCr ratio averaged over all young subjects of 
the AM muscle resulted in a lower PCr/TCr ratio compared to the other muscles. 
A one tailed t-test showed that this was lower compared to that of the 3 other 
muscles for which PCr/TCr ratios are available in all subjects: i.e. the ST (p<0.01), 
the SM (p< 0.03) and the BF (p=0.03). For all subjects and all muscles the average 
PCr/TCr ratio was 0.70±0.07.  
Figure 5: PCr/TCr ratio’s of the semi tendinosus muscle before, during and after Cr supplementation 
of the four young healthy volunteers. PCr/TCr ratios were determined from 13C spectra acquired and 
analyses as described in the materials and methods section. Bars indicate the mean values and the 
error bars indicate the standard deviation.
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Old and FSHD subjects
To test the feasibility of the 13C MRSI assessment of muscular creatine uptake 
in more fragile persons, i.e. a 82-year-old male and two FSHD patients, it was 
necessary to decrease the number of exams during the supplementation and 
thereafter. The creatine supplementation was well tolerated by all participants, and 
no side effects were reported. 
The female FSHD patient (FSHD#1) showed fatty infiltration in the AM and SM 
muscles, and the male FSHD patient (FSHD#2) showed severe fatty infiltration in 
the SM muscle, and minor fatty infiltration in the ST and BF muscles. The uptake 
rates could only be determined in the ST of FSHD#1, the AM of FSHD#2 and in 
the ST and SM of the 82-year-old male due to insufficient signal to noise of the 
creatine signals in spectra of other muscles (Fig 7A). The Cr uptake rates of the 
older male were found to be within the range of the values found in the healthy 
volunteers, while the FSHD values were found to be in the high range compared 
Table 3: Average muscular PCr/TCr ratios (mean ± SD)
Muscle Mean
ST 0.73 ± 0.04
SM 0.72 ± 0.03
AM 0.64 ± 0.03
BF 0.73 ± 0.07
G 0.69 ± 0.10
Figure 6: Muscle specific PCr/TCr ratios in young healthy volunteers (n=4). One-way ANOVA did not 
reveal statistical significant muscle specific effect. Bars indicate the mean PCr/TCr per volunteer and 
the error bars indicate the standard deviation.  
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to the young healthy subjects (Fig. 7A). The average PCr/TCr ratios of averaged 
over all muscles were similar to the values of the young healthy subjects with 
0.70±0.03 for the old healthy male and 0.70±0.07 for the FSHD patients (Fig. 7B).  
Figure 7: Grouped data including the young healthy subjects, FSHD patients and old healthy subject. 
A) The Cr uptake could only be determined in four muscles of the old and FSHD subjects. B) The PCr/
TCr ratios of the these subjects are within the range found in the young healthy subjects. YH: young 
healthy subjects, FSHD: FSHD patients, OH: old healthy subject.
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Discussion
In this work we demonstrate that 3D 13C MRSI is feasible for in vivo muscle specific 
determination of Cr uptake and turnover rates as well as the PCr/TCr ratios after 
labeled 13C Cr supplementation. Three dimensional proton and phosphorus MRSI 
have been applied in human leg studies34,35, but to the best of our knowledge 
this is the first demonstration of the in vivo application of 3D 13C MRSI in human 
legs. The Cr turnover was only determinable if creatine uptake was observed. This 
uptake rate was found to be higher in the young male subjects compared to the 
young women suggesting a gender effect. The PCr/TCr ratio is similar between 
the subjects for all investigated muscles and also between these muscles except 
for the AM in which this ratio was found to be significantly lower. 
Previously, we showed in a single male subject that 13C MRS is a feasible approach 
for non-invasive monitoring of Cr and PCr dynamics after supplementation 
of 13C labeled Cr24. In the present study we demonstrate that with 13C MRS in 
spectroscopic imaging mode we can spatially resolve metabolic information of 
multiple individual muscles in one exam. We applied this technique to monitor 
the fate of 13C4 Cr after oral supplementation of 13C labeled Cr in a diverse group 
of subjects, including young healthy volunteers, one healthy male over 80 years 
old, and two patients with FSHD. In this way Cr uptake and turnover is assessed 
instead of only the steady state level of the complete Cr pool, as has been done 
with 1H MRS after oral Cr ingestion20. 
We found a muscular Cr uptake rate that varied from 0 to 37% per day over all 
subjects and muscles. It is possible that the lack in Cr uptake observed in some 
muscles is because the subjects didn’t take the 13C labeled Cr as they were 
instructed. Therefore we analyzed blood plasma samples before and during the 
Cr supplementation period with mass spectroscopy to determine blood total Cr 
and 13C-Creatine concentration. These experiments showed an increase in Cr 
and 13C-4-Cr concentration for all subjects during the Cr supplementation period 
proving that they did ingest the provided 13C-Cr.
Differences in Cr response have been observed in rat hind limb muscles, with 
significant uptake in the gastrocnemius muscle but no response in the soleus 
muscle, an effect attributed to a higher contribution of type II fibers in the 
gastrocnemius36. However, this doesn’t seem to be the (complete) explanation 
for the variable uptake rates found in this study. Cr uptake rates were significantly 
higher in muscles of young healthy male subjects compared to the young healthy 
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females, but also to the rates in older male and FSHD patients. This result should 
be considered with some caution, as the group sizes were limited and also 
the number of muscles investigated (maximum 5 per subject). The differences 
between males and females may be caused by methodological issues such as 
sensitivity, or represent a real biological difference. For both young males and 
young females the MRSI voxel sizes were the same and similar values were found 
for field homogeneity, fat-fractions (2.8±0.8 vs. 1.2±0.3, p=0.08 two-tailed t-test) 
and creatine blood values. This suggests that the creatine uptake difference 
for the males and females in this study has a biological basis. Steady state 
muscular Cr levels are similar for males and females37,38, but creatine loading has 
significantly less effect on total body mass, fat free mass, muscle thickness and 
increase in lean body mass in females compared to males39,40. If this is due to a 
difference in Cr uptake between males and females needs to be confirmed in 
larger groups.  
The average muscular Cr turnover rate of 2.1±0.7% per day is in agreement 
with the results of our previous 13C MRS study of a single subject and with the 
reported non-enzymatic breakdown rates of creatine to creatinine (resp. 1.6 and 
1.7 % per day)2,24,33. The average PCr/TCr ratio (about 0.7) is remarkably constant 
over the investigated muscles and subjects and is comparable to some reported 
values14,41. For many Cr supplementation studies a higher increase in TCr than in 
PCr is reported42,43. As shown by Kan et al. for the gastrocnemius 24 and Brault et 
al. for the vastus lateralis muscle23 this is most likely due to an apparent artifact 
of the biopsy procedure. In the present study also no preferential increase of TCr 
is observed for another set of muscles, indicating a general preservation of the 
thermodynamic equilibrium of the creatine kinase reaction in muscle cells. The 
adductor magnus muscle showed a lower PCr/TCr ratio compared to the other 
investigated muscles (0.64±0.03). A possible explanation is a larger fiber type 
I contribution, but an autopsy studies revealed that AM has less type I than BF 
(respectively for AM: type I: 58% type II: 42% and for BF:  type I: 67% type II: 
33%)44. 
The T1 values of the 13C spin systems in Cr and PCr were found to be relatively 
short (≈400 ms), and the lower value for 13C Cr is in agreement with the results of 
our saturation studies performed in the gastrocnemius at 1.5T24.
Compared to our previous 13C MRS work24, for this 13C MRSI study we increased 
the field strength from 1.5T to 3T and the 13C enrichment from 10 to 15%. The 
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higher sensitivity allowed us to study 13C uptake and metabolism in individual 
muscles. In future studies a still higher enrichment may be recommended to 
compensate for a lower muscular uptake in females and older or diseased 
persons.   
In summary, after ingestion of 13C labeled Cr, 13C MRSI allows for subject and 
muscle specific determination of Cr uptake rate, Cr turnover rates and PCr/TCr 
ratios. The labeling degree used in the present study (15%) was sufficient to 
reliably determine the PCr/TCr ratio by measuring both PCr and Cr in a single 
measurement. Muscle specific Cr uptake and turnover rates were also determined, 
in particular in muscles of young healthy male subjects. Our results suggest a 
different muscular creatine uptake rate between males and females.
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Abstract
Purpose: to introduce myonavigation, a technique developed to selectively target 
and biopsy focal pathology in muscle tissue using per-procedural MRI, and to 
demonstrate that it is an accurate, safe, and well-tolerated procedure. 
Materials and Methods: ethical approval was obtained from the regional 
medical ethics review committee and written informed consent received from all 
participants. 13 Facioscapulohumeral muscular dystrophy patients aged 44-61 
years were included. Axial T1, T2 and TIRM imaging was performed to determine 
the appropriate target site in the vastus lateralis, after which a  myonavigation-
guided muscle biopsy was taken. Subsequently a conventional Bergström 
percutaneous needle biopsy of the tibialis anterior was performed. Differences in 
patient-reported pain scores between the two biopsy methods were analyzed with 
a paired samples two-sided T-test.  
Results: myonavigation-guided biopsies were successfully performed in all 
participants, even in those that had limited remaining muscle tissue. We were 
able to acquire muscle tissue from specific target areas, including areas showing 
focal pathological changes. The procedure was well tolerated by all participants, 
patient-reported pain scores did not differ between the MR-guided and 
conventional method (p= 0.310). 
Conclusion: myonavigation-guided biopsy is an accurate, safe and well-tolerated 
technique for the diagnosis, research, and treatment of muscle disorders.
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Introduction 
Sampling error is a common problem in muscle biopsies, especially in 
inflammatory myopathies where false-negative results occur in 10-20% of 
all biopsies due to focal disease activity1-3. In inherited myopathies such as 
facioscapulohumeral muscular dystrophy (FSHD), different disease stages can 
occur within a single muscle, rendering tissue collected with routine biopsy 
procedures not always histologically representative of the entire muscle, impeding 
a correct diagnosis and reliable research4,5. A more targeted approach is hence 
called for. 
Magnetic resonance imaging (MRI) allows an accurate identification of areas of 
inflammation and fatty infiltration in hereditary and inflammatory myopathies and 
in the latter has been used to select affected muscles prior to muscle biopsy6,7.
 
MRI-guided biopsy using per-procedural imaging is an established technique in 
the diagnosis of prostate and breast cancer and has drastically reduced sampling 
error in these diseases8,9. Based on these positive results, the purpose of this 
paper is to introduce myonavigation, a technique developed to selectively target 
and biopsy focal pathology in muscle tissue using per-procedural MRI, and to 
demonstrate that it is an accurate, safe, and well-tolerated procedure. 
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Materials and methods 
Patients and study design
As in FSHD muscle both localized fatty infiltration and focal inflammatory changes 
can be observed4, we included 13 genetically confirmed FSHD patients aged 
44-61 years. In- and exclusion criteria have been described previously10. Ethical 
approval was obtained from the regional medical ethics review committee and 
written informed consent received from all participants.
Imaging
MR measurements were conducted using a 3 Tesla MR system (Tim TRIO, 
Siemens, Erlangen, Germany) with patients being scanned in supine position, 
entering the magnet feet first. A fish oil capsule was placed at one third of the 
distance between the anterior superior iliac spine and the patella. To obtain 
maximum quality images, we used a spine array coil and two phased array coils 
covering the patient’s legs. For thigh muscle imaging, the table was positioned 
such that the upper leg was in the isocenter of the magnetic field. Myonavigation-
guided biopsies were obtained from the vastus lateralis muscle and Bergström 
percutaneous needle biopsies from the tibialis anterior muscle.  As a rule, we 
scanned the right leg unless manual muscle testing demonstrated asymmetrical 
weakness; in these cases the most severely affected leg was examined and 
biopsied. 
Diagnostic imaging
The MRI protocols were as previously described10. In brief, scout images were 
obtained in three orthogonal directions centered on the fish-oil marker, followed 
by axial T1-weighted images, T2-weighted images, and Turbo Inversion Recovery 
Magnitude (TIRM) images. 
Target area and needle trajectory
Based on the diagnostic imaging results, the appropriate target area for the 
myonavigation-guided biopsy was determined depending on the amount 
and location of remaining muscle tissue, fatty infiltration, and the presence of 
hyperintensities on TIRM suggestive of inflammation. In normal appearing tissue, 
the target area was set at the center of the vastus lateralis at the level of the fish 
oil marker (Fig 1). In case of inhomogeneous fatty infiltration, we targeted a site in 
the remaining muscle tissue adjacent to an area with fatty infiltration to increase 
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the chance of obtaining affected muscle tissue.  If focal TIRM hyperintensity was 
present, we performed a second myonavigation procedure to sample these areas. 
The trajectory of the biopsy needle (i.e., incision site, angle, and depth) was 
constructed based on anatomical 3D T1-weighted imaging (Fig 1; field of view 
269 x 269 x 160 mm; base resolution 384; repetition time 735 ms; echo time 2,54 
ms). 
Myonavigation-assisted biopsy
After the needle trajectory had been determined, a 4-mm incision was made 
at the appropriate site and an MR-compatible biopsy trocar inserted. A repeat 
T1-weighted 3D scan was performed to verify the position of the needle. If 
necessary, the trocar was repositioned accordingly. Taking routine antiseptic 
precautions, an experienced interventional radiologist performed the biopsy using 
a 9-gauge vacuum-assisted biopsy needle (Suros ATEC, Hologic, Bedford, USA). 
Subsequently, another 3D T1-weighted image as well as axial TIRM images were 
obtained to confirm the final biopsy site and to assess complications. If two target 
areas had been determined, a second biopsy was performed while adhering to 
the same protocol. 
The incision site was closed using steri-strips, after which a pressure bandage was 
applied. Positioning of the patient and diagnostic imaging took approximately 
Figure 1: Myonavigation-guided biopsy of the right vastus lateralis. 1A: The exact needle trajectory 
to the target area was determined by manually shifting anatomical 3D T1 images in at least three 
orthogonal planes. The appropriate needle angle (α°), depth, and insertion site relative to the fish oil 
marker was based on these images. 1B: A needle trocar was inserted after which a subsequent 3D T1 
was obtained to verify the position of the needle tip in the m. vastus lateralis. If necessary, the trocar 
was adjusted and repeat verification imaging performed. After positioning the needle into the correct 
site, a vacuum-assisted biopsy was taken. 
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20 minutes. The myonavigation procedure and biopsy took an additional 20-
50 minutes depending on the complexity of the target site and the number of 
biopsies scheduled.  
Safety and tolerability
Using a visual analogue scale (VAS), patients awarded pain scores after each 
myonavigation-guided and Bergström needle biopsy. Any physical complaints 
such as post-biopsy swelling or pain were noted. 
Histology
Biopsy material was frozen in isopentane and stored at -80°C. An experienced 
pathologist examined the size, shape, type, and cytoarchitecture of the muscle 
fibers, verifying the presence of internalized nuclei, the destruction of muscle 
fibers and regeneration, as well as supporting connective tissue. 
Statistics
Differences in patient-reported pain scores between the two biopsy methods were 
analyzed with a paired samples two-sided T-test. Data are represented as mean ± 
standard error of the mean (SEM), a p value <0.05 was considered significant. 
141
6
M
y
o
n
a
v
ig
a
t
io
n
 b
io
p
s
ie
s
Results 
Muscle biopsy procedures
MR images showed pathological changes compatible with FSHD4. Fatty infiltration 
of the vastus lateralis varied markedly between patients, ranging from <5% 
to >90%. In all 13 patients the target area in the vastus lateralis was reached 
and biopsied, even in those patients that had limited remaining muscle tissue. 
A second myonavigation-guided biopsy was successfully performed in two 
patients with focal TIRM positive changes, resulting in a total of 15 biopsies. 
All myonavigation procedures yielded enough muscle tissue for histological 
evaluation. Bergström needle biopsy of the tibialis anterior was performed on 11 
patients.
Safety and tolerability
VAS pain scores in patients that underwent both biopsy procedures were 
4.8 ± 0.8 after myonavigation compared to 3.9 ± 0.6 directly following the 
Bergström procedures (p = 0.310). Two symptomatic hematomas occurred after 
myonavigation-guided biopsy, resulting in self-limiting local pain and swelling. 
Furthermore, two asymptomatic hematomas were observed on control imaging 
performed directly after the myonavigation-guided biopsies. No complications 
were reported after the Bergström needle biopsies.
Multiple target sampling within a single muscle
In two participants we obtained multiple myonavigation-assisted biopsies from 
areas with distinct MRI changes in a single muscle. To reach the second target 
area, the same incision site could be used in one patient while in the other a 
second incision was needed. The results from one of these patients are shown in 
figure 2, depicting clear histological differences between samples collected from 2 
separate areas within the vastus lateralis. 
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Figure 2: Myonavigation allows the precise targeting of different disease stages within a single 
muscle. 2A: Diagnostic T1-weighted axial image of the left upper leg of a 50-year-old male FSHD2 
patient showing marked fatty infiltration of nearly all muscles. 2B: illustration showing target areas 
in * T1 hyperintense / TIRM hyperintense tissue and ** T1 hypointense adjacent to fatty infiltration 
/ TIRM hypointense tissue. 2C: Axial TIRM image showing focal hyperintensity in the vastus lateralis 
corresponding to inflammation in residual muscle tissue. 2D *: HE staining demonstrates severe 
dystrophic changes as reflected by the marked increase in fiber size variability, increased internal nuclei, 
regenerating fibers, and fatty infiltration. 2E **HE staining shows fiber size variability, increased internal 
nuclei, and few regenerating fibers corresponding to mild dystrophic changes. 
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Discussion 
The present study demonstrates that myonavigation-guided biopsy is a highly 
accurate, safe, and tolerable method for the collection of muscle biopsies. Per-
procedural imaging enabled us to reach precise target areas in muscles with 
focal changes and sites in severely affected muscles with limited residual muscle 
tissue, thereby reducing sampling error and the need for repeat biopsies. We 
also successfully biopsied different areas within a single muscle in two patients, 
enabling us to study different disease stages in the muscle tissue of these 
individual patients, thus eliminating bias caused by inter-individual variability.   
Muscle MRI is developing into an important tool to assist the selection of affected 
muscles prior to conventional Bergström needle or open biopsy and has been 
shown to reduce sampling error6,11. Myonavigation adds per-procedural imaging 
of the muscle with the needle in position, which allows selective targeting and 
definite confirmation of the biopsy site as well as a direct assessment of potential 
complications. 
Myonavigation was safe, with symptomatic post-biopsy hematomas occurring in 
two of 13 participants, resulting in self-limiting local pain and swelling. Although a 
retrospective review of 13,500 Bergstrom needle biopsies found that “perceptible 
and bothersome pain for >3 days” occurred in 0.04%12, in our tertiary referral 
center for neuromuscular disorders many patients report similar complaints after 
routine Bergström percutaneous needle biopsy. It is likely that minor complications 
such as small hematomas also occur after traditional biopsies but go un(der)
recognized because their presence and extent is not verified using imaging 
techniques.
Although the relatively small sample size of this study prevents us from performing 
a cost-effectiveness analysis, we can argue that, in general, myonavigation-
guided biopsy is more expensive than a Bergström needle biopsy due to the cost 
associated with disposable materials, MRI imaging, and the extended procedure 
duration. Nevertheless, we expect that myonavigation will be cost-effective in the 
diagnosis of selected cases with focal pathology and can serve as a valuable tool 
for research. 
Myonavigation has many potential applications. It is a valuable tool to reduce 
144
M
y
o
n
a
v
ig
a
t
io
n
 b
io
p
s
ie
s
6
sampling error and thereby facilitate the diagnosis of inflammatory myopathies 
and other muscle disorders with focal disease activity. The visualization of 
anatomic structures makes it possible to target virtually any muscle for sampling 
and perform per-procedural assessments of vascular and nerve supply. It can 
provide the precise histological confirmation of MRI findings and vice versa, while 
repeat imaging and biopsies can be used for longer-term follow-up in natural 
history studies. Finally, in clinical trials it may be used to deliver therapeutic 
agents, for example in AAV-mediated viral gene delivery. 
In conclusion, myonavigation is a promising new technique that will foster the 
diagnosis and research of muscle disorders while providing new insights that will 
help optimize care.
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Chapter 7 
Summary and future perspectives
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Facioscapulohumeral muscular dystrophy (FSHD) is one of the most frequent 
inherited muscular dystrophies1, and is characterized by progressive weakness and 
fatty infiltration of the muscles. This thesis describes work focusing on the muscle 
specific aspects of FSHD. The general aim was to uncover pathophysiological 
features of FSHD in a non-invasive way by MR imaging and spectroscopy. 
Summary
In chapter 1 the classification, genetics, histopathology, and clinical presentation 
specific to FSHD is described. In addition a general background in MRI physics 
is provided. Muscle and fat tissue have different T2 relaxation times giving rise 
to contrast differences in T2 MR images. With quantitative T2 MRI (qT2-MRI) 
the apparent T2 is a combination of the T2 contribution of fat and muscle, and 
therefore holds information on the relative contribution of either component. The 
signal intensity as a function of echo time is solely dependent on the contributing 
T2s of proton spins present in the voxel. If only two components (i.e. muscle and 
fat) are assumed to be present in muscles then fitting of the proton signal decay 
with a biexponential function, representing the distinct decay of each component, 
will provide the ratio of the two components. With this MR imaging procedure the 
fat-fraction of every voxel in the field of view of the image can be determined, see 
BOX3 of Chapter 1.
 
In chapter 2 we determined this fat-fraction in a muscle specific fashion in a large 
group of well-characterized FSHD patients. We showed that the amount of fat 
present in the thigh muscles correlate with the patients age, clinical severity and 
muscle strength. Secondly we observed that in FSHD patients fatty infiltration of 
the muscles is a dichotomous phenomenon, meaning that most of the muscles 
either have a normal fat content or are very heavily fat infiltrated. Interestingly 
we observed that especially in the muscles that have an intermediate fat-fraction 
(±13% of all investigated FSHD muscles) the intramuscular distribution of the fatty 
infiltration rises in the proximo-distal direction. In the same muscles we found 
the ATP/PCr ratio to be lower compared to normal levels. Most important we 
found that these intermediate fat infiltrated muscles showed the highest rate of 
fatty infiltration progression, suggesting the directionality of the fatty infiltration 
and the lower PCr/ATP ratio are indicative of a disease active state. Moreover we 
confirmed that in these muscles the disease progression is along the length of 
the muscle in the disto-proximal direction.  These differences along the muscle 
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length indicated that FSHD is a focal disease. Finally we demonstrated that 
TIRM hyperintense areas, suggestive for inflammation, show higher rates of fatty 
infiltration compared to TIRM normal areas. Whether the TIRM hyperintensities are 
a consequence of the active disease process or is the trigger for this progressive 
phase remains to be investigated.
Next to MRI, ultra sound (US) is also a common imaging modality to study 
neuromuscular diseases. For example it has been shown that US has a predictive 
value in disease prognostication in Duchenne muscular dystrophy. In chapter 3 
we compared quantitative MRI (QMRI or qT2-MRI) with quantitative muscle ultra 
sound (QMUS) in a small group of five male FSHD patients. With qT2-MRI the 
muscle specific fat-fraction is determined (value between 0% and 100%), whilst 
with QMUS the intensity of the gray scale image is converted to the z-score 
indicating the number of standard deviations the signal intensity is deviating 
from normal. This means that the z-score determined QMUS does not have a 
theoretical maximum and minimum value. qT2-MRI and QMUS correlated highly, 
but instead of following a simple linear relationship the parameters appeared 
to have a sigmoidal relation. This is due to the limited range of qT2-MRI and 
the unlimited range of QMUS. Even though the correlation between the two 
modalities was very high, this study exemplified that in muscle diseases having an 
uneven pathological distribution over the muscles length, like in FSHD, it is very 
important to consider a larger part of the muscle instead of a single slice. This 
was already implemented in the MRI protocol but not yet for the QMUS protocol. 
Furthermore this study included one patient who was classified with a very 
high clinical severity and reduced muscle strength, suggestive for an advanced 
disease state. However imaging, both MRI as US, showed normal musculature of 
the thighs. Upon second clinical examination it turned out his clinical limitations 
were due to his obesity, diabetes, and poor cardiovascular condition. With the 
incidence of obesitas and diabetes raising yearly it becomes even more important 
to distinguish true muscle weakness caused by a neuromuscular disease from a 
concurrent disorder, especially in therapy evaluation. These findings emphasize 
the potential important role of muscular imaging in the evaluation of clinical trials. 
Ergo in chapter 4 we applied qT2-MRI as an objective outcome measure in 
a clinical trial. More specifically a randomized clinical trial (RCT) that tested 
whether aerobic exercise therapy (AET) and cognitive behavioral therapy (CBT) 
are able to alleviate fatigue severity in FSHD patients suffering from severe 
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fatigue, which is reported in up to 60% of all FSHD patients in the Netherlands 
2. This RCT demonstrated that indeed these therapies are effective in lowering 
the fatigue level however a clear effect in the objective outcome measures on 
physical function was lacking 3. In this chapter we described results that show 
that progression of fatty infiltration decelerates after AET and CBT. This was the 
first demonstration that fat-fraction determined with qT2-MRI can be used as a 
sensitive and reproducible biomarker to reveal therapy effects in FSHD. Even 
though no treatment effects could be established on the six-minute walk test, 
average thigh fat-fractions correlate highly with these classical outcome measures. 
Because of the high-specificity qT2-MRI goes beyond these measurements in the 
assessment of the therapies for neuromuscular diseases
This trial was the first RCT in which a therapeutic effect could be established 
for FSHD. Previously trials have been conducted for instance with prednisone4, 
albuterol5 or creatine mono-hydrate6 however these trials were inconclusive.  There 
is a wide variation in the responsiveness to creatine supplementation between 
individuals, which may be because creatine uptake depends on conditions such 
as intracellular creatine concentration and fiber type ratio. The evaluation of 
creatine supplementation also lacks a method to monitor creatine uptake non-
invasively in individual muscles. Therefore we developed a new method using 13C 
MR spectroscopic imaging (MRSI) in combination with oral intake of 13C-labeled 
creatine for the assessment of muscle specific creatine metabolism (see chapter 
5). In a feasibility study this was applied to 4 young healthy volunteers, 1 older 
person and 2 FSHD patients. Additional to demonstrating the feasibility of this 
technique the results of the muscle creatine uptake suggest a gender specific 
effect to creatine responsiveness. This method also allowed us to determine the 
ratio of phosphocreatine to unphosphorylated creatine, which was observed to be 
remarkable similar for all muscles in all subjects, except for the adductor magnus, 
which has a slightly lower relative phosphocreatine. This indicates that that the 
myocellular creatine kinase reaction in vivo is in thermodynamic equilibrium. 
Taking muscle biopsies remains common practice in the diagnosis and research 
of muscle diseases. However, this is prone to sampling errors, as muscle biopsies 
may not represent the condition of the whole muscle, in particular if the disease 
manifests itself in focal way. In chapter 2 we described that this also applies 
to FSHD, suggesting that routine biopsy yields muscle tissue that possibly 
does not represent the entire muscle or the most active disease area. This calls 
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for a targeted approach in the biopsy procedure and therefore we introduce 
Myonavigation biopsy in chapter 6. This is a novel technique to selectively target 
and collect muscle tissue using per-procedural MRI. In this chapter we show that 
Myonavigation biopsy is a safe and tolerable technique that has the advantage 
of providing a direct comparison between histology and MRI. Moreover, in one 
example we show that the different disease stages occurring in one muscle could 
be confirmed by histological examination of two tissue samples of a single muscle 
of a single FSHD patient. 
Future perspectives
Since the genetic origin of FSHD has been uncovered research towards 
possible treatments has gained momentum7. However, understanding the exact 
pathophysiology underlying the disease still largely remains unresolved. But 
with the current knowledge efforts are being made to reach consensus on the 
disease pathophysiology8. The main findings of the research presented in this 
thesis demonstrate that the disease can manifest itself very locally in affected 
muscles, that disease progression has a specific directionality in muscle fibers, and 
that increased physical daily activity has a beneficial effect. These findings hint 
to an underlying disease mechanisms. Edema detected by MR, which occurs in 
about 5% of the FSHD muscles, is most likely caused by an active inflammatory 
process9,10. As this edema usually presents itself adjacent to the regions that are 
replaced by fatty tissue, this indicates that either inflammation is part of disease 
progression, possibly by triggering DUX4 gene activation leading to a cascade 
of disease progression as described in by Tassin et al11, or that fatty infiltration 
is causing the surrounding muscle tissue to become inflamed, which in itself 
may promote further disease progression. If muscle inflammation is causing 
disease progression in FSHD, the anti-inflammatory effects of exercise may 
explain the beneficial effect of increased physical activity. In muscle contractions 
specific anti-inflammatory cytokines are released and lipid turnover and lipolysis 
is increased12,13. To further test this hypothesis a relationship between anti-
inflammatory cytokines and disease progression should be established. However 
this would be very challenging since FSHD disease activity and progression can 
occur very locally in muscles and may be variable in time for an individual muscle. 
Although biopsies rather than general blood-plasma analyses are preferred for 
such studies they are difficult to standardize and execute. Myonavigation biopsy 
may have a potential role here as it is able to accurately collect tissue from a 
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targeted area, and allows for a follow-up of this area, for instance by TIRM imaging 
to monitor inflamed muscle sections. Levels of anti-inflammatory cytokines may 
be manipulated either by exercising the targeted muscle or by a pharmaceutical 
intervention. In the latter case the Myonavigation biopsy procedure may serve 
a twofold purpose; besides collecting a biopsy from a targeted area it may also 
deliver a therapeutic agent to a specific site in muscles.  
Besides further investigating the underlying causes of the beneficial effects of 
AET and CBT in FSHD, it is worthy to extensively research the effects of these 
interventions on other muscle diseases. In the FACTS-2-NMD program these AET 
and CBT interventions are being applied to FSHD, post polio syndrome (PPS) and 
amyotrophic lateral sclerosis (ALS), all these trials focus on reducing fatigue by 
these interventions. Presently, during the preparation of this thesis, the results of 
these trials have yet to be published, however MRI’s were not included in the PPS 
and ALS trials. Although in those diseases muscle inflammation is not expected 
to play a progressive role in the disease and an effect similar to what we found in 
FSHD may not be expected, decrease of fatigue severity appears to occur that 
is very beneficial to these patients. Similar effects as in FSHD may be found in 
other muscles disease in which muscle inflammation is present like inclusion body 
myositis, polymyositis or even Duchenne muscular dystrophy. 
qT2-MRI is a promising biomarker for therapy evaluation in neuromuscular 
diseases. In a randomized control trial the expected effect size determines the size 
of the groups. The effect size depends on the expected effect difference (average 
group A – average group B) and the variation on the measurement (standard 
deviation group A/B). Neuromuscular dystrophies are rare diseases, and even 
though the patients are usually motivated to enter in scientific studies, it remains 
challenging to achieve large group sizes (>100)14. In this thesis we used qT2-MRI 
to determine the fat-fraction, and we determined the standard deviation of this 
method to be 6.5% (Appendix to chapter 4). From a sample size calculation it 
can be determined that size effects of over 8% would be detected in group-sizes 
as small of 9 participants. For a general muscle specific analysis 9 participants 
would yield data on ~90 muscles and treatment effects as small as 2.5% would 
be uncovered. Because of this high sensitivity the incorporation of qT2-MRI as 
an outcome measure in RCT’s in neuromuscular diseases could potentially steer 
the search for effective treatments. In this way treatment effectiveness will be 
established faster and within smaller patient cohorts. 
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Another benefit of including MRI in clinical trials is its ability, unlike muscle 
strength measurements, to differentiate between muscle disease and concurring 
conditions like diabetes and obesity. Besides MRI also QMUS could be used for 
this purpose. Furthermore QMUS has a larger dynamic range than qT2-MRI, which 
may reveal information on advanced disease progresses like reorganization of the 
muscle connective tissue. 
A final note on the use of qT2-MRI as a muscular biomarker is about the various 
ways to analyze the datasets acquired by this method. In the past five years 
several research groups have published different methods to analyze these data 
and to reveal information on various parameters like the general T2 relaxation 
time, the water T2 relaxation time, the fat content, or the edema content15-19. 
This indicates that qT2-MRI includes more information than only the fat-muscle 
ratios. However at present the scientific field is struggling with what information is 
exactly within the datasets, how to get it out and of what the clinical significance 
the information is. Potentially qT2-MRI will be able to provide us with quantitative 
information on healthy muscle, edema, inflammation, fibrosis and fatty infiltration. 
Nevertheless first all these various methods have to be compared and tested on a 
similar but varied dataset and consensus has to be reached on how to analyze and 
present this valuable qT2-MRI data. 
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Chapter 8
Samenvatting en 
toekomstperspectieven
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Facioscapulohumeral spier dystrofie (FSHD) is een van de meest voorkomende 
erfelijke spierdystrofieën1, en wordt gekarakteriseerd door progressieve 
spierzwakte en vervetting van de spieren. Dit proefschrift beschrijft werk dat focust 
op de spier specifieke aspecten van FSHD. Het algemene doel van dit proefschrift 
was om pathofysiologische aspecten van FSHD bloot te leggen met behulp van 
non-invasieve MR imaging en spectroscopie. 
Samenvatting
De classificatie, genetica, histopathologie, en klinische presentatie van FSHD is 
beschreven in hoofdstuk 1. Daarnaast wordt er algemene achtergrondinformatie 
gegeven over de MRI fysica. Spier- en vetweefsel hebben verschillende T2 
relaxatie tijden en hebben daardoor een verschillend contrast in T2 gewogen MR 
beelden. Bij kwantitatieve T2 MRI (qT2-MRI) wordt de ogenschijnlijke T2 bepaald, 
die in werkelijkheid een combinatie is van een T2 bijdrage van vet en spier, en 
bevat daarom informatie over de relatieve contributie van beide componenten. 
De signaal intensiteit als functie van de echo tijd is enkel afhankelijk van de 
bijdragende T2s van de proton spins aanwezig in het voxel. Als er vanuit wordt 
gegaan dat er alleen twee componenten (i.e. spier en vet) aanwezig zijn in de 
spier dan zal het fitten van de proton signaal afname met een biexponentiële 
functie, waarbij elk component onderscheidend wordt vertegenwoordigd, de 
ratio van beide componenten opleveren. Met deze MR imaging procedure kan de 
vetfractie van iedere voxel in het gezichtsveld van het MR image worden bepaald, 
zie BOX3 van Hoofdstuk 1.
 
In hoofdstuk 2 bepalen we deze vetfractie op een spier specifieke wijze in een 
grote groep goed geclassificeerde FSHD patiënten. We hebben laten zien dat de 
hoeveelheid vet dat aanwezig is in de dijspieren correleert met de leeftijd van de 
patiënt, zijn klinische aangedaanheid en spiersterkte. Ten tweede observeerden 
we dat vervetting in FSHD een dichotoom fenomeen is, wat inhoud dat de 
meeste spieren of een normale vet hoeveelheid hebben of zeer zwaar vervet zijn. 
Interessant genoeg zagen we dat vooral in de spieren met een tussenliggende 
vetfractie (±13% van alle onderzochten FSHD spieren) de intramusculaire 
distributie van de vervetting stijgt in de proximo-distale richting. In dezelfde 
spieren hebben we een lagere ATP/PCr ratio gevonden dan wordt gevonden 
in normale spieren. Allerbelangrijkst is dat deze middelmatig vervetten spieren 
de hoogste vervettingsnelheid laten zien. Dit suggereert dat er een voor een 
specifieke richting van vervetting is en dat de verlaagde PCr/ATP indicatief is voor 
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een actief ziekte proces. Bovendien hebben we kunnen bevestigen dat progressie 
van de vervetting over de lengte van spier verloopt, wel te verstaan in de disto-
proximale richting. Deze verschillen over de lengte van de spier wijzen erop dat 
FSHD een focale ziekte is. Als laatste hebben we laten zien dat hyperintense 
gebieden op TIRM beelden (T2 gewogen MR beelden met vetonderdrukking), 
suggestief voor ontsteking, een hogere vervettingsnelheid vertonen dan TIRM 
normale gebieden. Of dat een TIRM hyperintensiteit een gevolg van het actieve 
ziekte proces is of juist de trigger is van deze progressieve fase moet nog verder 
worden onderzocht.
Naast MRI is ook ultra sound (US) een veelgebruikte beeldvormende techniek 
voor het bestuderen van spierziekten. Er is bijvoorbeeld aangetoond dat US een 
voorspellende waarde heeft in de prognosticering in Duchenne spier dystrofie. 
In hoofdstuk 3 vergelijken we kwantitatieve MRI (QMRI of qT2-MRI) met 
kwantitatieve spier ultra sound (QMUS) in een kleine groep van vijf mannelijke 
FSHD patiënten. Met qT2-MRI wordt de spier specifieke vetfractie bepaald (een 
waarde tussen 0% en 100%), terwijl er bij QMUS de grijsschaal intensiteit wordt 
omgezet naar een z-score, en geeft daarmee het aantal standaard deviaties aan 
dat de grijsschaal van normaal afwijkt. Dit betekent dat de z-score bepaald met 
QMUS in theorie geen maximum of minimum heeft. qT2-MRI en QMUS  hebben 
een hoge correlatie, maar in plaats van een simpele lineaire relatie blijken de 
parameters een sigmodiale  relatie te hebben. Dit komt door de beperkte range 
van qT2-MRI en de ongelimiteerde range van QMUS. Naast een hoge correlatie 
tussen de twee modaliteiten laat deze studie zien dat in spierziekten waarin de 
pathologie een ongelijke distributie over de lengte van de spier heeft, zoals in 
FSHD, het erg belangrijk is om een groter gedeelte van de spier te bekijken dan 
een enkele slice. Dit hadden we al geïmplementeerd in het MRI protocol maar 
nog niet in het QMUS protocol. Daarnaast zat er in deze studie een patiënt die 
geclassificeerd was met een hoge klinische aangedaanheidsscore en verminderde 
spiersterkte, duidend op een vergevorderde ziekte status. Beeldvorming, zowel 
MRI als US, liet echter een normaal spierstelsel van de dij zien. Bij een secundair 
klinisch onderzoek bleek dat zijn klinische beperkingen het gevolg waren van 
zijn obesitas, diabetes, en slechte cardiovasculaire conditie. Met de oplopende 
incidentie van obesitas en diabetes wordt het steeds belangrijker om spierzwakte 
als gevolg van een spierziekte te kunnen onderscheiden van een gelijktijdige 
aandoening, met name bij therapie evaluatie. Deze bevindingen benadrukken de 
potentiele rol van spier imaging voor de evaluatie in klinische trials. 
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Ergo in hoofdstuk 4 passen we qT2-MRI toe als een objectieve uitkomstmaat 
in een klinische studie, specifieker een gerandomiseerde klinische trial (RCT) die 
onderzocht of aerobe training (AET) en cognitieve gedragstherapie (CBT) helpen 
bij het verminderen van zware vermoeidheid, waar meer dan 60% van de FSHD 
patiënten in Nederland last van heeft2. Deze RCT liet zien dat deze therapieën 
effectief zijn in het verminderen van de vermoeidheid, een duidelijk effect op 
een objectieve uitkomstmaat werd echter niet gevonden3. De resultaten in dit 
hoofdstuk laten zien dat de progressie van spiervervetting vertraagd wordt na 
AET en CBT. Dit is de eerste demonstratie dat vervetting bepaald met qT2-MRI 
gebruikt kan worden als een sensitieve en reproduceerbare uitkomstmaat om 
therapie effecten aan te tonen in FSHD. Ondanks dat er geen therapie effecten 
konden worden vastgesteld op basis van de zes-minuten-looptest, correleerde 
deze klassieke uitkomstmaat sterk met de gemiddelde vervetting van de 
dijspieren. Omdat qT2-MRI zeer specifiek is gaat deze uitkomstmaat verdere 
dan de klassieke uitkomstmaten die veel gebruikt voor therapie evaluatie in 
neuromusculaire ziekten. 
Deze trial was de eerste waarin een therapeutisch effect kon worden vastgesteld 
in FSHD. Voorheen zijn er trials uitgevoerd om de effecten te onderzoeken 
van prednison4, albuterol5 of creatine mono-hydraat6, de uitkomsten van deze 
studieswaren echter niet overtuigend van een positief interventie-effect. Er is een 
wijde variatie in de responsiviteit op creatine suppletie tussen individuen, dit is 
mogelijk te verklaren doordat creatine opname afhankelijk is van condities zoals 
intracellulaire creatine concentratie en vezeltype verhouding. Een methode om 
de creatine opname non-invasief te evalueren in specifieke spieren was echter 
nog niet beschikbaar. In hoofdstuk 5 presenteren we een nieuwe methode 
gebruik makend van 13C MR spectroscopische imaging (MRSI) in combinatie met 
orale inname van 13C-gelabeled creatine voor de spier specifieke evaluatie van 
creatine metabolisme. In een haalbaarheidsstudie hebben we deze techniek 
toegepast in vier gezonde jonge vrijwilligers, een oudere man en twee FSHD 
patiënten. Naast het aantonen van de haalbaarheid van deze techniek suggereren 
onze resultaten dat creatine opname verschilt tussen mannen en vrouwen. Deze 
methode heeft ons ook in staat gesteld om de verhouding tussen gefosforyleerde 
en ongefosforyleerde creatine te bestuderen. Dit bleek gelijk te zijn voor de 
onderzochte spieren (i.e. de hamstrings) behalve voor de adductor magnus spier, 
welke een relatief lagere fosfocreatine liet zien. Dit geeft aan dat de myocellulaire 
creatine kinase reactie in thermodynamische evenwicht is. 
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Het nemen van spierbiopten blijft een veelgebruikte techniek in het 
diagnosticeren en bestuderen van spierziekten. Desondanks is deze techniek 
gevoelig voor bemonsteringsfouten; de gehele conditie van de spier wordt 
mogelijk niet vertegenwoordigd door het spierbiopt, met name in het geval van 
focale ziekten. In hoofdstuk 2 hebben we beschreven dat dit ook geldt voor FSHD, 
dit suggereert dat een routine biopt spierweefsel kan opleveren dat mogelijk niet 
de gehele spier vertegenwoordigd noch het gedeelte waarin de ziekte het meest 
actief is. Dit vraagt om een gerichte biopsie procedure en daarom introduceren 
we Myonavigatie biopsie in hoofdstuk 6. Dit is een nieuwe techniek om een 
specifieke locatie van de spier te selecteren en biopteren gebruik makend van 
per-procedurele MRI. In dit hoofdstuk laten we zien dat Myonavigatie biopsie een 
veilige en goed getolereerde techniek is die het voordeel heeft dat er een directe 
vergelijking tussen histologie en MRI gemaakt kan worden. Bovendien laten we 
in een voorbeeld zien dat de verschillende ziekte stadia aanwezig in een spier, 
zoals we hebben gezien op MRI, nu bevestigd kunnen worden met histologie door 
histologisch onderzoek van twee weefselmonsters uit een enkele spier van een 
FSHD patiënt. 
Toekomstperspectieven 
Sinds dat de genetische oorsprong van FSHD ontdekt is er meer aandacht voor 
onderzoek richting potentiele behandelingen voor deze patiënten7. Desondanks 
blijft het begrijpen van het exacte onderliggende pathofysiologische mechanisme 
achter. Er worden echter wel pogingen gewaagd om consensus te bereiken over 
de pathofysiologie van de ziekte8. De voornaamste bevinding van het onderzoek 
gepresenteerd in dit proefschrift laat zien dat de ziekte zich zeer gelokaliseerd 
kan manifesteren in aangedane spieren, dat progressie van de ziekte gericht door 
de spiervezels verloopt, en dat een toename aan fysieke activiteit een positief 
effect heeft. Deze bevindingen hinten naar een onderliggend ziektemechanisme. 
Spier oedeem dat wordt gezien op MRI, in ongeveer 5% van alle FSHD spieren, 
wordt waarschijnlijk veroorzaakt door een actieve ontsteking9,10. Dit oedeem 
wordt voornamelijk gezien naast de gebieden vervangen door vetweefsel, 
dit geeft aan dat een ontsteking ofwel een gedeelte van het ziekteproces is, 
mogelijk door geïnitieerde DUX4 gen activatie wat leidt tot een cascade van 
ziekteprogressie zoals beschreven door Tassin et al11, ofwel dat de vervetting 
ontsteking veroorzaakt in het omliggende spierweefsel en op die manier verdere 
progressie van de ziekte bevordert. Als spierontsteking progressie in FSHD 
veroorzaakt of bevordert dan zou het kunnen zijn dat de anti-inflammatoire 
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effecten van spieractivatie de positieve effecten van verhoogde fysieke activiteit 
verklaart. Tijdens spiercontracties wordt vetomzetting bevordert en komen er 
anti-inflammatoire cytokines vrij12,13. Om deze hypothese verder te testen zou er 
een relatie tussen circulerende anti-inflammatoire cytokines en ziekte progressie 
moeten worden vast gesteld. Dit zal echter zeer uitdagend zijn omdat in FSHD 
activiteit en progressie van de ziekten zich zeer lokaal kunnen voordoenen en ook 
variëren over de tijd. Ondanks dat biopsieën meer geschikt zouden zijn voor dit 
soort onderzoek in vergelijking tot algemene bloedplasma analyses zijn biopten 
moeilijker uit te voeren en te standaardiseren. Myonavigatitie biopsie zou hier 
een potentiele rol kunnen spelen omdat het in staat is accuraat een biopt te 
nemen van een uitgekozen gebied, bovendien maakt het follow-up van dat exacte 
gebied mogelijk. Zo zou er bijvoorbeeld op de TIRM beelden ontstoken gebieden 
gevolgd kunnen worden over de tijd. Concentraties van anti-inflammatoire 
cytokines kunnen gemanipuleerd worden door training of een farmaceutische 
interventie. In dat laatste geval zou de Myonavigation biopsie procedure een 
tweevoudig doel kunnen hebben; naast het nemen van een biopt op een 
nauwkeurig geselecteerd gebied zou het ook een therapeutisch middel in de spier 
kunnen achterlaten. 
Naast het verder onderzoeken van de onderliggende mechanismen die de 
positieve effect van AET en CBT in FSHD zouden kunnen verklaren, is het de 
moeite waard om te onderzoeken of deze vormen van interventie eenzelfde 
effect hebben in andere spierziekten. In het FACTS-2-NMD programma worden 
de AET en CBT interventies toegepast in FSHD, post polio syndroom (PPS) en 
amyotrofe laterale sclerose (ALS), al deze trials focussen op het verminderen van 
vermoeidheid en daarom zijn MRI’s geen onderdeel van de PPS en ALS trials 
geworden. Op dit moment, tijdens het afronden van dit proefschrift, moeten 
de resultaten van deze trials nog gepubliceerd worden. Omdat in deze ziekten 
spierontsteking waarschijnlijk geen rol speelt bij de progressie zou een effect zoals 
we hebben gevonden in FSHD ook niet te verwachten zijn. Dit neemt niet weg dat 
een verlaagd vermoeidheidsniveau van de patiënten een zeer positief therapie 
effect is. Effecten zoals we die in FSHD hebben gevonden kunnen mogelijk ook 
worden gevonden in andere spierziekten waarin spierontsteking aanwezig is zoals 
‘inclusion body’ myositis, polymyositis of zelfs Duchenne spierdystrofie. 
qT2-MRI is een veelbelovende biomarker voor therapie evaluatie in 
neuromusculaire ziekten. In een gerandomiseerd klinische trial wordt de grootte 
van de groepen bepaald door de grootte van het te verwachten effect. Het te 
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verwachten effect hangt af van het te verwachten verschil tussen de groepen 
(gemiddelde groep A – gemiddelde groep B) en de variatie van de meting 
(standard deviatie groep A/B). Neuromusculaire spier dystrofieën zijn zeldzame 
ziekten, en ondanks dat de patiënten over het algemeen gemotiveerd zijn deel te 
nemen aan wetenschappelijke studies blijft het een uitdaging om grootte groepen 
te includeren (>100)14. In dit proefschrift gebruiken we qT2-MRI om de vetfractie 
te bepalen, we hebben ook bepaald dat de standaard deviatie van deze methode 
6.5% is (zie appendix van hoofdstuk 4). Als met die standaard deviatie een sample 
size (groepsgrootte) berekening gedaan wordt komt daaruit dat een groepseffect 
van 8% gedetecteerd kan worden met groepen vanaf 9 deelnemers. Als er bij 9 
deelnemers een spier specifieke analyse zou worden gedaan levert dat al snel 
data op van ~90 spieren per deelnemer en daarmee zou een behandelingseffect 
van 2.5% al kunnen worden vastgesteld. Op deze manier kan effectiviteit van een 
behandeling snel en in een kleine patiënten groep worden vastgesteld. Deze 
hoge sensitiviteit van qT2-MRI zou er voor kunnen zorgen dat de incorporatie van 
deze uitkomstmaat in RCT’s bij neuromusculaire ziekten in potentie de zoektocht 
naar effectieve behandelingen zou kunnen sturen. 
Een ander voordeel van het toevoegen van MRI aan een klinische trial is dat het 
in staat is onderscheid te maken tussen de spierziekte en andere samenvallende 
aandoeningen zoals diabetes en obesitas, in tegenstelling tot krachtmetingen. 
Naast MRI kan ook QMUS dit doel dienen. Daarnaast heeft QMUS een groter 
dynamisch bereik dan qT2-MRI, wat mogelijk informatie kan opleveren over 
vergaande ziekte progressie zoals de reorganisatie van het bindweefsel.
 
Een laatste noot over het gebruik van qT2-MRI als een spier biomarker gaat 
over de verschillende methode waarop de verkregen datasets geanalyseerd 
kunnen worden. In de laatste vijf jaar hebben verschillende onderzoeksgroepen 
verschillende methoden gepubliceerd om deze data te analyseren en om 
informatie over verschillende parameters naar boven te halen, zoals de algemene 
T2 relaxatietijd, de T2 relaxatietijd van water, de vervettingsgraad, of de mate 
van oedeem15-19. Dit laat zien dat qT2-MRI meer informatie bevat dan alleen de 
vet-spier verhouding. Desondanks wordt er in het huidige wetenschappelijke 
landschap geworsteld met welke informatie exact in de datasets aanwezig is, 
hoe het eruit te krijgen en wat deze klinische significantie van de informatie is. In 
potentie kan qT2-MRI kwantitatieve informatie geven over gezonde spierweefsel, 
oedeem, ontsteking, fibrosis en vet infiltratie. Daarvoor moeten al deze 
verschillende methoden getest en vergeleken worden op dezelfde welgevarieerde 
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dataset en moet er consensus bereikt worden hoe deze waardevolle qT2-MRI data 
te analyseren en te presenteren.
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ik nou super enthousiast over iets ben of juist over iets in de put zit, jij hebt mij 
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